US20030143569A1 - Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor - Google Patents
Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor Download PDFInfo
- Publication number
- US20030143569A1 US20030143569A1 US10/210,307 US21030702A US2003143569A1 US 20030143569 A1 US20030143569 A1 US 20030143569A1 US 21030702 A US21030702 A US 21030702A US 2003143569 A1 US2003143569 A1 US 2003143569A1
- Authority
- US
- United States
- Prior art keywords
- solid support
- group
- immobilized
- thiol groups
- nucleic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007787 solid Substances 0.000 title claims abstract description 273
- 238000000034 method Methods 0.000 title claims abstract description 141
- 239000003446 ligand Substances 0.000 title claims abstract description 77
- 230000003100 immobilizing effect Effects 0.000 title claims abstract description 22
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 190
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 189
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 184
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 184
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims abstract description 101
- 230000003213 activating effect Effects 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims description 118
- 125000001931 aliphatic group Chemical group 0.000 claims description 62
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 56
- 238000006116 polymerization reaction Methods 0.000 claims description 47
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 claims description 42
- 125000003342 alkenyl group Chemical group 0.000 claims description 41
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 39
- 239000011521 glass Substances 0.000 claims description 34
- -1 silane compound Chemical class 0.000 claims description 31
- 150000003254 radicals Chemical class 0.000 claims description 29
- 239000003999 initiator Substances 0.000 claims description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 125000000524 functional group Chemical group 0.000 claims description 26
- 229920000642 polymer Polymers 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 24
- 239000004793 Polystyrene Substances 0.000 claims description 22
- 229920002223 polystyrene Polymers 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 125000003277 amino group Chemical group 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 16
- 239000003638 chemical reducing agent Substances 0.000 claims description 16
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 14
- 238000002493 microarray Methods 0.000 claims description 14
- 229910000077 silane Inorganic materials 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000002228 disulfide group Chemical group 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 229910052763 palladium Inorganic materials 0.000 claims description 9
- 229910052697 platinum Inorganic materials 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000000903 blocking effect Effects 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 150000002825 nitriles Chemical class 0.000 claims description 7
- 239000011534 wash buffer Substances 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- XFXPMWWXUTWYJX-UHFFFAOYSA-N isonitrile group Chemical group N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000010453 quartz Substances 0.000 claims description 6
- 238000001712 DNA sequencing Methods 0.000 claims description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000000356 contaminant Substances 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 238000013507 mapping Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 239000000956 alloy Substances 0.000 claims description 3
- 229910052793 cadmium Inorganic materials 0.000 claims description 3
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- 239000010937 tungsten Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 239000011133 lead Substances 0.000 claims description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- 239000000499 gel Substances 0.000 description 59
- 239000000523 sample Substances 0.000 description 39
- 108091034117 Oligonucleotide Proteins 0.000 description 37
- 238000009396 hybridization Methods 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 30
- 239000000872 buffer Substances 0.000 description 28
- 150000003573 thiols Chemical group 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 0 [1*][Si]([2*])([3*])C Chemical compound [1*][Si]([2*])([3*])C 0.000 description 25
- 239000004005 microsphere Substances 0.000 description 25
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 24
- 229910001868 water Inorganic materials 0.000 description 20
- 239000010410 layer Substances 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 16
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 16
- 239000002299 complementary DNA Substances 0.000 description 15
- 239000008363 phosphate buffer Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 14
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 14
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 14
- 239000007984 Tris EDTA buffer Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 9
- DJVKJGIZQFBFGS-UHFFFAOYSA-N n-[2-[2-(prop-2-enoylamino)ethyldisulfanyl]ethyl]prop-2-enamide Chemical compound C=CC(=O)NCCSSCCNC(=O)C=C DJVKJGIZQFBFGS-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000012491 analyte Substances 0.000 description 8
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 7
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 6
- PVTPPHDBKXHYSH-UHFFFAOYSA-N C=CC(=O)NCSSCNC(=O)C=C Chemical compound C=CC(=O)NCSSCNC(=O)C=C PVTPPHDBKXHYSH-UHFFFAOYSA-N 0.000 description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000006196 deacetylation Effects 0.000 description 6
- 238000003381 deacetylation reaction Methods 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- ABEZALRGXDQDIC-UHFFFAOYSA-N C.C=CC(=O)NCSSCNC(=O)C=C Chemical compound C.C=CC(=O)NCSSCNC(=O)C=C ABEZALRGXDQDIC-UHFFFAOYSA-N 0.000 description 5
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 241000208199 Buxus sempervirens Species 0.000 description 4
- FWAWJTCVYOCSGR-UHFFFAOYSA-N C=CC(=O)NCSSCNC(=O)C=C.[HH].[HH] Chemical compound C=CC(=O)NCSSCNC(=O)C=C.[HH].[HH] FWAWJTCVYOCSGR-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 108700031620 S-acetylthiorphan Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000018146 globin Human genes 0.000 description 4
- 108060003196 globin Proteins 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000002019 disulfides Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 150000004662 dithiols Chemical class 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- RXRHXOLQBOFMDI-UHFFFAOYSA-N methoxymethane;2-methylprop-2-enoic acid Chemical compound COC.CC(=C)C(O)=O RXRHXOLQBOFMDI-UHFFFAOYSA-N 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 150000004756 silanes Chemical class 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- ZRTJVRDXVSDKPX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-acetylsulfanylpropanoate Chemical compound CC(=O)SCCC(=O)ON1C(=O)CCC1=O ZRTJVRDXVSDKPX-UHFFFAOYSA-N 0.000 description 1
- PSRGGEQXKSZPRF-UHFFFAOYSA-N (4-nitrophenyl) prop-2-enoate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)C=C)C=C1 PSRGGEQXKSZPRF-UHFFFAOYSA-N 0.000 description 1
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- KBQVDAIIQCXKPI-UHFFFAOYSA-N 3-trimethoxysilylpropyl prop-2-enoate Chemical compound CO[Si](OC)(OC)CCCOC(=O)C=C KBQVDAIIQCXKPI-UHFFFAOYSA-N 0.000 description 1
- JRPYIBOHLMGQST-UHFFFAOYSA-N 4-[3-[2-(prop-2-enoylamino)ethyldisulfanyl]propanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCSSCCNC(=O)C=C JRPYIBOHLMGQST-UHFFFAOYSA-N 0.000 description 1
- ILAYIAGXTHKHNT-UHFFFAOYSA-N 4-[4-(2,4,6-trimethyl-phenylamino)-pyrimidin-2-ylamino]-benzonitrile Chemical compound CC1=CC(C)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 ILAYIAGXTHKHNT-UHFFFAOYSA-N 0.000 description 1
- BCZUPRDAAVVBSO-MJXNYTJMSA-N 4-acetylcytidine Chemical compound C1=CC(C(=O)C)(N)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BCZUPRDAAVVBSO-MJXNYTJMSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- VSCNRXVDHRNJOA-PNHWDRBUSA-N 5-(carboxymethylaminomethyl)uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CNCC(O)=O)=C1 VSCNRXVDHRNJOA-PNHWDRBUSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LJPPDESLSQOQIO-UHFFFAOYSA-N [Hg].[Pb] Chemical compound [Hg].[Pb] LJPPDESLSQOQIO-UHFFFAOYSA-N 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- IPVPURUWKGWQQV-UHFFFAOYSA-N aminophosphonous acid;prop-2-enamide Chemical class NP(O)O.NC(=O)C=C IPVPURUWKGWQQV-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108700013698 bio-adhesio-chemo protocol Proteins 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical class Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical class CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000003854 isothiazoles Chemical class 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- NCKZHFSVCRZQGH-UHFFFAOYSA-N methylsulfinylmethane;phosphoric acid Chemical compound CS(C)=O.OP(O)(O)=O NCKZHFSVCRZQGH-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 150000002780 morpholines Chemical group 0.000 description 1
- PBWRQSSISZQGFM-UHFFFAOYSA-N n'-hydroxybutanediamide;prop-2-enoic acid Chemical compound OC(=O)C=C.NC(=O)CCC(=O)NO PBWRQSSISZQGFM-UHFFFAOYSA-N 0.000 description 1
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
- AWGZKFQMWZYCHF-UHFFFAOYSA-N n-octylprop-2-enamide Chemical compound CCCCCCCCNC(=O)C=C AWGZKFQMWZYCHF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RQAGEUFKLGHJPA-UHFFFAOYSA-N prop-2-enoylsilicon Chemical compound [Si]C(=O)C=C RQAGEUFKLGHJPA-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- PZJJKWKADRNWSW-UHFFFAOYSA-N trimethoxysilicon Chemical compound CO[Si](OC)OC PZJJKWKADRNWSW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
Definitions
- a variety of assay systems utilize ligands, e.g., nucleic acids, immobilized on the surface of a solid support. Effective immobilization of the nucleic acids is difficult, both because a range of materials are used to form the solid supports utilized in these assays, and because individual assays have special requirements. Therefore, although a number of attachment mechanisms have been developed, none are universally acceptable and most exhibit notable deficiencies. Among other drawbacks, present methods tend to require large amounts of nucleic acids, have high background noise levels or lack versatility (Duran et al. U.S. Pat. No. 5,858,653 issued Jan. 12, 1999).
- the present invention is based, at least in part, on the discovery of a novel and convenient method of mobilizing a ligand, e.g., a nucleic acid, on a solid support.
- the method utilizes a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on the nucleic acid to immobilize the nucleic acid to the support.
- the covalent bond formed is a sulfide, a thioether, bond.
- the solid support can contain a polymer layer.
- the method and the supports it produces are advantageous in several respects.
- the method utilizes reagents which are both readily available and compatible with the types of analysis conducted with solid supports. Because the materials can be used in aqueous solutions, the need for special skills and sophisticated chemical apparatus are minimized. In addition, because the materials and the supports they form are quite stable, the reproducibility from support to support which has previously proved so difficult to achieve can be realized. This stability also permits the components forming the bond to be combined at different times. For example, because solid supports containing the latent thiol groups of the invention are extremely stable, they can be produced under consistent conditions for use at a later time.
- the latent thiol groups can be activated and contacted with the acrylamide modified nucleic acids to form a support containing immobilized nucleic acids.
- the thiol groups are activated by contact with a reducing agent.
- the invention is directed to a method of immobilizing an affinity ligand on a solid support comprising providing a solid support comprising an immobilized thiol group, contacting the thiol group with a nucleic acid comprising an acrylamide functional group, and forming a covalent bond between the two groups, thereby immobilizing the ligand on the solid support.
- the ligand is a nucleic acid, a modified nucleic acid or a nucleic acid analog.
- the solid support can comprise a plurality of thiol groups. A plurality of ligands can be immobilized on the solid support.
- the solid support is formed from glass, silica, ceramic, plastic or metal compounds.
- the solid support can comprises two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids.
- the solid support can further comprise a polymer layer.
- the solid support can comprise a microarray.
- the thiol groups can comprise disulfide groups.
- the invention is directed to a method of immobilizing an affinity ligand on a solid support comprising the steps of providing a solid support comprising immobilized latent thiol groups, activating the latent thiol groups, and reacting the activated thiol groups with an affinity ligand having at least one acrylamide functional group, thereby immobilizing an affinity ligand on a solid support.
- the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog.
- the steps of activating the latent thiol groups and reacting the activated thiol groups can occur essentially simultaneously.
- the solid support is formed from glass, ceramic, plastic and metal.
- the solid support can comprise two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids.
- the solid support can further comprises a polymer layer.
- the solid support can comprise a microarray.
- the invention is directed to the product formed by the method of forming a solid support described above.
- the invention is directed to a method of immobilizing an affinity ligand on microarray comprising the steps of providing a solid support comprising immobilized latent thiol groups, activating the latent thiol groups, and reacting the activated thiol groups with an affinity ligand having at least one ⁇ , ⁇ unsaturated carbonyl functional group, thereby immobilizing an affinity ligand on a solid support.
- the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog. The steps of activating the latent thiol groups and reacting the activated thiol groups canoccur essentially simultaneously.
- the invention is directed to a method of immobilizing an affinity ligand on microarray comprising the steps of providing a solid support comprising immobilized latent thiol groups, the latent thiol groups and reacting the activated thiol groups with an affinity ligand having at least one ⁇ , ⁇ unsaturated carbonyl functional group, thereby immobilizing an affinity ligand on a solid support.
- the ligand is a nucleic acid, a modified nucleic acid or a nucleic acid analog. The steps of activating the latent thiol groups and reacting the activated thiol groups can occur essentially simultaneously.
- the method can additionally include contacting a glass solid support with a silane compound to form a solid support having an unsaturated aliphatic surface.
- the silane compound can be represented by Structural Formula I:
- X is a halogen
- R 1 , R 2 and R 3 are each, independently, a halogen, an alkyl group, an alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, provided that at least one of R 1 , R 2 or R 3 is an alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl.
- the unsaturated aliphatic surface is then contacted with a polymerization solution containing free radical initiator, a disulfide bisacrylamide, and optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups.
- Disulfide bisacrylamides can be represented by Structural Formula IIA:
- n and m are each, independently, a positive integer.
- the latent thiol groups can be activated by contacting the solid support with a disulfide reducing agent.
- the polymerization solution can additionally include alkylene bisacrylatide.
- the unsaturated aliphatic surface is then contacted with a polymerization solution containing free radical initiator, a compound having a ⁇ , ⁇ -unsaturated carbonyl and a protected thiol group, and optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups.
- a polymerization solution containing free radical initiator a compound having a ⁇ , ⁇ -unsaturated carbonyl and a protected thiol group
- optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups.
- the compound having an ⁇ , ⁇ -unsaturated carbonyl and a protected thiol group preferably can be represented by Structural Formulas IIB-IID:
- R 11 and R 4 are defined as above.
- R 14 is —(CH 2 ) p - or —(OCH 2 CH 2 ) p -.
- R 4 is —SR 15 , wherein R 15 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted aralkyl group.
- a bifunctional disulfide reagent is BAC.
- a monofunctional disulfide reagent is AEMA (Schnaar, R. L. et al., 1985, Analytical Biochemistry, 151:268-281). Additional monofunctional acrylamide disulfide derivatives can be generated by reacting BAC with the reducting agents ⁇ -mercaptoethanol and thioacetic acid, as shown if FIGS. 8 and 9.
- the free radical initiator is added to the polymerization solution after the solution is in contact with the unsaturated aliphatic surface of the solid support.
- the method can additionally include derivatizing the solid support with a latent thiol group, thereby forming a solid support having immobilized latent thiol groups.
- the solid support includes an amine functional group and the solid support is derivatized by contacting the solid support with a compound represented by Structural Formula III:
- Y is a leaving group
- L is a linking group
- R 4 is a thiol protecting group.
- the derivatized solid support formed has immobilized latent thiol groups.
- Y is one of the following:
- R 6 and R 7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- R 4 is one of the following groups:
- R 8 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- the invention is directed to a method of preparing a solid support having immobilized thiol groups.
- the method includes contacting a glass solid support with a silane compound represented by Structural Formula I to form a solid support having an unsaturated aliphatic surface.
- the unsaturated aliphatic surface of the solid support is then contacted with a polymerization solution containing free radical initiator, a disulfide bisacrylamide represented by Structural Formula IIA-D, and optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups.
- the latent thiol groups of the solid support are then contacted with a disulfide reducing agent to form a solid support having immobilized thiol groups.
- the solid support is doped or undoped silica, alumina, quartz or glass
- the method further comprises the steps of contacting the solid support with a compound comprising a silane group or a carboxylic acid and a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- the compound can be represented by the following structural formula:
- R 1 , R 2 and R 3 are each, independently, a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, provided that at least one of R 1 , R 2 or R 3 is a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl.
- the latent thiol groups can be activated by contacting the solid support with a disulfide reducing agent.
- the polymerization solution can further include alkylene bisacrylamide.
- the free radical initiator can be added to the polymerization solution after the solution is in contact with the unsaturated aliphatic surface of the solid support
- the solid support can be gold, silver, copper, cadmium, zinc, palladium, platinum, mercury, lead, iron, chromium, manganese, tungsten, and alloys thereof, and the method can further comprises the steps of contacting the solid support with a compound comprising a thiol group, sulfide or disulfide group and a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing a conmonomer, wherein the disulfide bisacrylamide is represented by the following structural formula:
- n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- the solid support can be platinum or palladium, and the method can further comprises the steps of contacting the solid support with a compound comprising a nitrile or isonitrile group and a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- the solid support can be copper, and the method can further comprise the steps of contacting the solid support with a compound comprising a hydroxamic acid group and a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator and disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- the solid support can be a polymer comprising a reactive functional group
- the method can further comprise the steps of contacting the solid support with a compound comprising a functional group which can react to form a bond with the reactive functional group and a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, thereby forming a solid support having immobilized unsaturated aliphatic group, and contacting the unsaturated aliphatic groups of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- the polymeric solid support can be polystyrene.
- the reactive functional group of the polymeric solid support can be an amine group or a hydroxyl group and the compound is represented by the following structural formula:
- Y is a leaving group
- L is a linking group
- R 10 is a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl.
- Y can be:
- R 6 and R 7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- the method can further comprise the step of derivatizing a solid support with a latent thiol group, thereby forming a solid support having immobilized latent thiol groups.
- the solid support can be doped or undoped silica, alumina, quartz or glass, and the solid support can be derivatized by contacting it with a compound comprising a silane group or a carboxylic acid group and a latent thiol group.
- the solid support can be platinum or palladium, and the solid support is derivatized by contacting it with a compound comprising a nitrile or isonitrile group and a latent thiol group.
- the solid support can be a polymer comprising reactive functional groups, and the solid support is derivatized by contacting it with a compound comprising a functional group which can react to form a bond with the reactive functional group and a latent thiol group.
- the polymeric solid support can be polystyrene.
- the reactive functional group of the polymeric solid support can be an amine or a hydroxyl group and the solid support can be derivatized by contacting the solid support with a compound represented by the following structural formula:
- Y is a leaving group
- L is a linking group
- R 4 is a thiol protecting group, thereby forming a solid support having immobilized latent thiol groups.
- Y can be:
- R 6 and R 7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- R 4 can be:
- R 6 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- the invention is directed to a method of making a solid support having immobilized thiol groups, comprising the steps of contacting a glass solid support with a silane compound represented by the following structural formula:
- R 1 , R 2 and R 3 are each, independently, a halogen, an alkyl group, an alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, provided that at least one of R 1 , R 2 or R 3 is an alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups, and contacting the latent thiol groups with a disulfide reducing agent, thereby forming a solid support having immobilized thiol groups.
- the invention is directed to a method of forming an array of nucleic acids immobilized on a solid support including forming an amine-derivatized region on the support, treating the amine-derivatized region with a thiolating agent such that latent thiol groups immobilized on the support are formed, activating the latent thiol groups, contacting the activated thiol groups with a plurality of nucleic acids comprising acrylamide functional groups, and forming a covalent bond between the two groups, thereby forming an array of nucleic acids immobilized on the solid support.
- each nucleic acid contained in the array includes a nucleotide sequence identical to or substantially identical to, the nucleotide sequence of the other nucleic acids of the array, or nucleic acids with a plurality of nucleotide sequences are contained in the array.
- the solid support can include a plurality of amine-derivatized regions.
- the method can further include a step of blocking any unbonded reactive thiol groups remaining following the binding of the nucleic acids to the thiol groups.
- kits for attaching nucleic acids to a solid support including a solid support component including a plurality of immobilized latent thiol groups and instructions for activating the thiol groups to form covalent bonds with nucleic acids including acrylamide functional groups.
- kits can also include an activator component, an acrylamide functional nucleic acids component, a blocking component and/or a wash buffer.
- the invention is directed to a kit for attaching nucleic acids to a solid support including a solid support component including a plurality of immobilized latent thiol groups and nucleic acids including acrylamide functional groups.
- the nucleic acids are immobilized on the solid support by a covalent bond between the immobilized thiol groups and the nucleic acids.
- kits can also include an activator component, a blocking component and/or a wash buffer.
- the invention is directed to a method for detecting or separating target nucleic acids from other components contained in a sample including providing a solid support comprising a plurality of immobilized nucleic acids comprising nucleotide sequences complementary to a subsequence of the nucleotide sequence of the target nucleic acid, wherein the nucleic acids are immobilized by a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on the nucleic acid, contacting the immobilized nucleic acid with the test sample, and hybridizing target nucleic acids to immobilized nucleic acids with complementary subsequences, thereby separating target nucleic acids from other components contained in the sample.
- the target nucleic acids can be amplified.
- the method can be used in an assay for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
- the invention is directed to a method for detecting or separating target nucleic acids from other components contained in a sample including providing a solid support comprising a plurality of immobilized thiol groups, contacting the thiol groups with a plurality of nucleic acids comprising nucleotide sequences complementary to a subsequence of the nucleotide sequence of the target nucleic acid and acrylamide functional groups, forming a covalent bond between the two groups, thereby immobilizing the nucleic acids on the solid support, contacting the immobilized nucleic acids with the test sample, and hybridizing target nucleic acids to immobilized nucleic acids with complementary subsequences, thereby detecting or separating target nucleic acids from other components contained in the sample.
- the target nucleic acids can be amplified.
- the method can be used in an assay for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
- FIG. 1 is a schematic representation of a method of derivatizing an amine group bearing polystyrene support with an acrylamide derivatized oligonucleotide.
- FIG. 2A is a representation of a solid support selectively treated to activate latent thiol groups.
- FIG. 2B is a representation of a solid support in which reactive groups are blocked, then exposed to acrylamide functional oligonucleotides.
- FIG. 3A is a photograph showing results of microarray formation on a N,N′ bis(acryloyl)cystamine (BAC) coated slide in which excess thiol groups were blocked with dimethylacrylamide (DMA).
- BAC N,N′ bis(acryloyl)cystamine
- FIG. 3B is a photograph showing results of microarray formation on a N,N′ bis(acryloyl)cystamine (BAC) coated slide in which excess thiol groups were blocked with 2-hydroxymethacrylate (HEMA).
- BAC N,N′ bis(acryloyl)cystamine
- FIG. 4 is a plot of fluorescent intensity across a spot for slides prepared with 2% N,N′ bis(acryloyl)cystamine (BAC) or 2% N,N′ bis(acryloyl)cystamine(BAC) plus P400 mm.
- BAC N,N′ bis(acryloyl)cystamine
- BAC N,N′ bis(acryloyl)cystamine
- FIGS. 5 A- 5 C are photographs showing a N,N′ bis(acryloyl)cystamine (BAC) acrylate slide after hybridization to fluorescent complementary oligonucleotide probes.
- BAC N,N′ bis(acryloyl)cystamine
- FIG. 6 is a bar graph illustrating the results obtained from a comparison of hybridizations performed using Tris-Glycine buffer and those performed using carbonate buffer.
- FIG. 7 is a bar graph illustrating the results of an experiment showing the influence of buffer and glycerol in spotting solution on hybridization signal for 10 ⁇ l probe spots.
- FIG. 8 is a schematic of a synthesis for a non-symmetrical disulfide acrylamide.
- FIG. 9 is a schematic of a synthesis for a non-symmetrical disulfide acrylamide.
- the present invention is based, at least in part, on the discovery of a novel and convenient method of immobilizing an affinity ligand on a solid support.
- the method utilizes a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on an affinity ligand to immobilize the affinity ligand to the support.
- the covalent bond formed is a sulfide, a thioether, bond.
- the method and the supports it produces are advantageous in several respects.
- the method utilizes reagents which are both readily available and compatible with the types of analysis conducted with solid supports. Because the materials can be used in aqueous solutions, the need for special skills and sophisticated chemical apparatus are minimized. In addition, because the materials and the supports they form are quite stable, the reproducibility from support to support which has previously proved so difficult to achieve can be realized. This stability also permits the components forming the bond to be combined at different times. For example, because solid supports containing the latent thiol groups of the invention are extremely stable, they can be produced under consistent conditions for use at a later time.
- the latent thiol groups can be activated and contacted with the acrylamide modified nucleic acids to form a support containing immobilized nucleic acids.
- the thiol groups are activated by contact with a reducing agent.
- the method is directed to a method of immobilizing an affinity ligand on a solid support.
- the method includes providing a solid support comprising an immobilized thiol group, contacting the thiol group with an affinity ligand comprising an acrylamide functional group, and forming a covalent bond between the two groups, thereby immobilizing the affinity ligand on the solid support.
- affinity ligand is intended to include any molecule that can form a specific binding complex with a target analyte and can be immobilized on a suitable solid support. Any suitable ligand can be used in the present invention provided that it can form a specific binding complex with a target analyte. Methods for determining the thermal stability of binding complexes and, in particular, hybridization complexes are well known in the literature. Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26:227-259 (1991); Quartin and Wetmur, Biochemistry, 28:1040-1047 (1989).
- an affinity ligand is a single-stranded nucleic acid, which can bind by hybridization, for example, to an analyte that contains a complementary nucleic acid sequence.
- the single stranded nucleic acid affinity ligand can be complementary to the entire analyte nucleic acid sequence or to a portion thereof.
- Single-stranded nucleic acids can also be used for isolation of duplex nucleic acids by triplex formation (Hogan and Kessler, U.S. Pat. No. 5,176,966 and Cantor, et al., U.S. Pat. No. 5,482,836, the teachings of which are incorporated herein by reference).
- Double-stranded nucleic acids can also serve as useful affinity ligands for nucleic acid binding proteins, or for nucleic acid analytes that bind to the ligand by triplex or tetraplex formation.
- the conditions under which a single stranded nucleic acid will bind to another nucleic acid to be immobilized on a solid support can be estimated by those skilled in the art using the procedure referenced above.
- the melting temperature (T m ) of the two nucleic acids provides a reasonable framework for estimating the temperate at which an nucleic acid analyte will hybridize to a nucleic acid affinity ligand.
- the T d is lower than the T m by about 15 to 25° C. and, therefore, the temperature at which the gel should be run to facilitate specific hybridization between the analyte and affinity ligand should be about 15 to 25° C. or more below the T m .
- Nucleic acid aptamers can also be used as affinity ligands in the process of the present invention.
- Aptamers can be selected against many kinds of analytes, including proteins, small organic molecules, and carbohydrates (reviewed in Klug and Famulok, Molecular Biology Reports (1994), 20:97-107).
- selection of aptamer ligands offers a simple and flexible mechanism for obtaining affinity ligands against virtually any target molecule.
- Other useful ligands include proteins or polypeptides which can bind to specific analytes.
- An especially useful class of protein ligands are antibody molecules, which can be elicited against a wide range of analytes by immunization methods.
- Antibodies ligands can be monoclonal or polyclonal.
- a fragment of an antibody can be an affinity ligand.
- receptor proteins may be useful as ligands for purification and detection of analytes that bind to or are bound by them.
- Carbohydrates have been successfully used as affinity ligands for electrophoretic purification of lectins (Horejsi and Kocourek, Biochim. Biophys. Acta (1974), 336:338-343), and may be useful for purification and detection of molecules that bind to specific carbohydrates or glycoproteins.
- Binding or non-binding conditions of proteins, aptamers and lectins for specific ligands can be estimated using the procedure outlined above for estimating the stability of analyte/affinity ligand complexes.
- equilibrium dialysis experiments can provide a rational method of predicting the stability of analyte/affinity ligand complexes.
- the dissociation constant of a protein for a particular ligand can be determined in the electrophoresis buffer at several different pHs, temperatures or ionic strengths. The higher the dissociation constant, the weaker the binding between the protein and the ligand (see Segel, I. H., Biochemical Calculations, 2 nd Edition (1976), John Wiley & Sons, New York, p. 241-244). From this data a binding and a non-binding condition can be estimated.
- immobilized ligands include peptides, amino acids, nucleosides, small organic molecules, lipids, hormones, drugs, enzyme substrates, enzyme inhibitors, enzymes, coenzymes, inorganic molecules, chelating agents, macromolecular complexes, polysaccharides, monosaccharides, and others.
- a nucleic acid can be utilized as an affinity ligand.
- Such nucleic acids include deoxyribonucleic acid (hereinafter “DNA”), or ribonucleic acid hereinafter “RNA”), modified nucleic acids, nucleic acid analogs, and chimeric molecules of a mixed class comprising a nucleic acid with another organic component, e.g., peptide nucleic acids.
- Nucleic acids can be single-stranded or double-stranded nucleic acids.
- the length of a nucleic acid will be at least about 5 nucleotides in length, more typically between about 5 and 100 nucleotides even more typically between 5 and 50, although it can be as long as several thousand bases.
- nucleic acids are typically “isolated” nucleic acids, e.g., nucleic acids separated away from the components of their source of origin (e.g., as it exists in cells, or in a mixture such as a library) and can have undergone further processing.
- Isolated nucleic acids include nucleic acids obtained by methods known to those of skill in the art.
- isolated nucleic acids include substantially pure nucleic acids, e.g., nucleic acids free from protein, carbohydrate or lipids.
- Nucleic acids can be produced by chemical synthesis, or by combinations of biological and chemical methods or by recombinant methods.
- modified nucleic acid is intended to include nucleic acids containing modified bases, deoxyribose groups or phosphates.
- nucleic acids having modified bases include, for example, acetylated, carboxylated or methylated bases e.g, 4-acetylcytidine, 5-carboxymethylaminomethyluridine, 1-methylinosine, norvaline or allo-isoleucine.
- nucleic acid analog is intended to include molecules that lack a conventional deoxyribose/ribose-phosphodiester backbone, but which retain the ability to form Watson-Crick type base pairs with complementary single-stranded nucleic acids.
- nucleic acid analogues include peptide nucleic acids (PNAS; Egholm et al., 1992, J. Am. Chem. Soc. 114: 1895-1897) and morpholino oligomers (morpholinos; Summerton and Weller, Antisense Nucleic Acid Drug Dev. , (1997)7:187-195). It will be apparent to those skilled in the art that similar design strategies can be used to construct other nucleic acid analogs that will have useful properties for immobilized probe assays.
- alkyl group is intended to include straight chained or branched C 1 -C 18 hydrocarbons which are completely saturated, or cyclic C 3 -C 18 hydrocarbons which are completely saturated.
- Lower alkyl groups are straight chained or branched C 1 -C 3 hydrocarbons or C 3 -C 8 cyclic hydrocarbons which are completely saturated.
- Alkyl groups are preferably lower alkyl groups.
- alkenyl group is intended to include straight chained or branched C 1 -C 18 hydrocarbons which have one or more double bond, or cyclic C 3 -C 18 hydrocarbons which have one or more unconjugated double bond.
- Lower alkenyl groups are straight chained or branched C 1 -C 8 hydrocarbons which have one or more double bond or C 3 -C 8 cyclic hydrocarbons which have one or more unconjugated double bond.
- Alkenyl groups are preferably lower alkenyl groups.
- aromatic group is intended to include carbocyclic aromatic ring systems (e.g., phenyl) and carbocyclic aromatic ring systems fused to one or more carbocyclic aromatic or non-aromatic ring (e.g., naphthyl, anthracenyl and 1,2,3,4-tetrahydronaphthyl).
- carbocyclic aromatic ring systems e.g., phenyl
- carbocyclic aromatic ring systems fused to one or more carbocyclic aromatic or non-aromatic ring e.g., naphthyl, anthracenyl and 1,2,3,4-tetrahydronaphthyl.
- Heteroaromatic groups include heteroaryl ring systems (e.g., thienyl, pyridyl, pyrazole, isoxazolyl, thiadiazolyl, oxadiazolyl, indazolyl, furans, pyrroles, imidazoles, pyrazoles, triazoles, pyrimidines, pyrazines, thiazoles, isoxazoles, isothiazoles, tetrazoles, or oxadiazoles) and heteroaryl ring systems in which a carbocyclic aromatic ring, carbocyclic non-aromatic ring, heteroaryl ring or a heterocycloalkyl ring is fused to one or more other heteroaryl rings (e.g., benzo(b)thienyl, benzimidazole, indole, tetrahydroindole, azaindole, indazole,
- heteroaryl ring systems
- aralkyl group is intended to include aromatic substituents that are linked to a moiety by an alkyl group that preferably has from one to about six carbon atoms.
- heteroaromatic substituents that are linked to a moiety by an alkyl group that preferably has from one to about six carbon atoms.
- heterocycloalkyl group is intended to include non-aromatic ring systems that preferably has 5 to 6 atoms and include at least one heteroatom, such as nitrogen, oxygen, or sulfur.
- heterocycloalkyl groups include morpholines, piperidines, and piperazines.
- Suitable substituents for aliphatic groups, aromatic groups, aralkyl groups, heteroaromatic groups and heterocycloalkyl groups include aromatic groups, halogenated aromatic groups, lower alkyl groups, halogenated lower alkyl (e.g. trifluoromethyl and trichloromethyl), —O-(aliphatic group or substituted aliphatic group), —O-(aromatic group or substituted aromatic group), benzyl, substituted benzyl, halogens, cyano, nitro, —S-(aliphatic or substituted aliphatic group), and —S-(aromatic or substituted aromatic).
- linking group includes substituted or substituted alkyl groups, substituted or unsubstituted aromatic groups, substituted or unsubstituted aralkyl groups and substituted or unsubstituted polyether groups.
- the affinity ligands of the invention comprise a ⁇ , ⁇ -unsaturated carbonyl group.
- a preferred ⁇ , ⁇ -unsaturated carbonyl group is an acrylamide.
- acrylamide is intended to include compounds represented by Structural Formula IV:
- R 11 is —H, or a substituted or unsubstituted alkyl group. In a preferred embodiment, R 11 is a —H or a methyl group.
- An affinity ligand can be derivatized with a selectively thiol reactive group.
- thiol reactive groups can include methacrylate, methacrylamide, ⁇ , ⁇ unsaturated carbonyl groups [CH2CHC(F2)], ⁇ , ⁇ unsaturated difluoro groups and maleimide groups.
- such groups show enhanced reactivity with thiol groups, as opposed to other functional gorups present in the reaction.
- a bifunctional disulfide reagent is BAC.
- a monofunctional disulfide reagent is AEMA (Schnaar, R. L. et al., 1985, Analytical Biochemistry, 151:268-281). Additional monofunctional acrylamide disulfide derivatives can be generated by reacting BAC with the reducting agents ⁇ -mercaptoethanol and thioacetic acid, as shown if FIGS. 8 and 9.
- acrylamide group is intended to include those groups which are represented by Structural Formula V:
- R 11 is defined as in Structural Formula IV.
- “ ⁇ ” represents the point of attachment of the affinity ligand.
- a peptide or protein can be derivatized with an acrylamide group by reacting an amine group with an acrylic acid in the presence of a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide.
- the amine group of the peptide or protein can react with the acrylic acid to form an acrylamide group represented by Structural Formula V.
- Methods for coupling peptide or protein amine groups with carboxylic acid group, such as the carboxylic acid group of an acrylic acid can be found in Stewart and Young, Solid Phase Peptide Synthesis, 2nd Edition, Pierce Chemical Company, Rockford, Ill., the entire teachings of which are hereby incorporated by reference.
- Carbohydrates, antigens or drug molecules which have an amine group can also be coupled with acrylic acid to form an acrylamide group using a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide.
- a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide.
- the carboxylic acid group of acrylic acid can be converted into an active ester, such as a p-nitrophenol acrylate, a o,p-dinitrophenol acrylate, or N-hydroxysuccinamide acrylate, and then allowed to react with an amine group of a carbohydrate, antigen or drug molecule.
- a thiol group is a group of the formula —SH.
- the term “latent thiol group” is intended to include thiol groups which have been protected with a thiol protecting group and disulfide groups of a polymer matrix.
- the term “thiol protecting group” is intended to include groups which can react with a thiol group causing the thiol group to be unreactive and which can be removed to regenerate the thiol group. Thiol protecting groups are known to those skilled in the art.
- thiol protecting groups can include the following groups:
- AcryditeTM phosphoramidite refers to the proprietary acrylamide phosphoranidite sold by Mosaic Technologies, Waltham, Mass. This product allows addition of an acrylamide group directly to a DNA or an RNA oligonucleotide using standard beta-cyanoethylphosphoramidite methods.
- AEMA is intended to encompass the compound known as 4-[[1-Oxo-3-[[2-[(1-oxo-2-propenyl)-amino]ethyl]dithio]propyl]amino]butanoic acid which was obtained from Ronald L. Schnaar, Department of Pharmacology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Md. (Schnarr, R. L. et al., 1985 Analytical Biochemistry 151:268-281).
- APS is intended to encompass an ammonium persulfate such as that available from BioRad Laboratories, Inc., Hercules, Calif.
- acrylate slide is intended to encompass a slide, e.g, a lass microscope slide, coated with an organosilane compound that includes an acrylamide or acrylic ester functionality.
- organosilane compound that includes an acrylamide or acrylic ester functionality.
- Such slides can be generated by treatment with (3′-acryloxypropyl)trimethoxysilane or other similar compounds available commercially, for example, from Gelest, Tullytown, Pa.
- Such slides can also be commercially obtained for example, from CEL Associates, Inc., Houston, Tex., (see Cat.# ACR-25C).
- BAC is intended to encompass the compound known as N,N′-bis(acryloyl)cystamine available, for example, from Fluka; Buchs, Switzerland.
- DMA dimethylacrylamide
- DMSO dimethyl sulfoxide
- DTNB is intended to encompass the compound known as 5,5′-dithio-bis-(2-nitrobenzoic) acid.
- HEMA is intended to encompass the compound known as 2-hydroxymethacrylate.
- P400 mm is intended to encompass compounds known as pol(yethylene glycol) 400 monomethyl ether monomethacrylate.
- SATP is intended to encompass the compound known as N-succinimidyl S-acetylthiopropionate available, for example, from Pierce; Rockford, Ill.
- SBB sodium borate buffers
- SDS sodium dodecyl sulfate
- SSPE standard saline phosphate EDTA buffers.
- TAA is intended to encompass thioacetic acids.
- TCEP is intended to encompass the compound known as tris(2-carboxyethyl) phosphine hydrochloride.
- TE buffer is intended to encompass a 10 mM Tris-HCl pH 8.3; 1 mM EDTA buffer.
- TEMED is intended to encompass compounds known as N,N,N′,N′-tetra-methyl-ethylenediamine available, for example, from BioRad Laboratories, Inc., Hercules,
- GMS spotter is intended to include a “GMS 417 Arrayer” (Affymetrix; Santa Clara, Calif.).
- the thiol protecting group is a disulfide group.
- Disulfide protecting groups can be removed by treating with a disulfide reducing agent which reduces the disulfide bond to form two thiol groups.
- Disulfide reducing agents include compounds such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP), ⁇ -mercaptoethanol and dithiothreitol.
- a solid support having immobilized thiol groups is contacted with an affinity ligand of the invention, which has been derivatized with an acrylamide group.
- the thiol groups can react with the acrylamide group of the affinity ligand to form a covalent bond via a Michael condensation reaction to form a solid support having immobilized affinity ligands. Therefore, although the term “immobilized” when used in reference to other methods can encompass various means of attachment to a solid support including both ionic and covalent types of bonding, when used in reference to the present invention “immobilized” refers to attachment with a covalent bond.
- the solid supports of the invention can be formed from a variety of materials including paper, glass, silica, metals, ceramics, plastic and polymers. Polymers can be cross-linked to form gels, e.g., electrophoretic gels, e.g., acrylamide gels.
- the solid supports can be of any shape or dimension. Porous filters, woven materials and meshes, planar sheets, microparticles, fibers, rods, optical fibers, dipsticks, beads, tubes, multiwell plates, cups and capillaries can all be used as solid supports.
- the solid support of the invention is formed of glass, silica, metal, ceramic or a polymer such as polystyrene, crosslinked polystyrene, polyethylene, polypropylene, polyrmethacrylate, dextran and agarose and a polymer layer is applied to a surface of the solid support.
- the solid support is formed of glass and a polymer layer is applied to a surface of the solid support.
- the solid support is planar in form and contains a polymer layer applied to a surface.
- an aliphatic group having a substituted or unsubstituted alkenyl group or a ⁇ , ⁇ -unsaturated carbonyl group is attached to a surface by contacting the surface with an aliphatic group which has been derivatized with a group that can bind to the surface, thereby forming an unsaturated aliphatic surface. Therefore, selection of a functional group with which the aliphatic group is to be derivatized is dependent on the type of material to which the aliphatic group is to be attached.
- the aliphatic group is preferably derivatized with a silane group or carboxylic acid.
- the compound can be represented by Structural Formula I.
- a glass or silica support is treated with an appropriate organosilane compound to provide a surface layer comprising a plurality of alpha-beta unsaturated groups.
- Preferred silanes include alkoxysilanes and chlorosilanes having vinyl, allylic, acrylamide, methacrylamide or acrylic ester functionalities.
- One preferred silane is (3′-acryloxpropyl)trimethoxysilane. This and other preferred silanes are commercially available from, for example, Gelest (Tullytown, Pa.).
- the aliphatic group to be attached is preferably derivatized with a thiol, sulfide or disulfide group.
- the aliphatic group is preferably derivatized with a nitrile or isonitrile group.
- the aliphatic group is preferably derivatized with a hydroxamic acid group.
- An acrylamide gel having latent thiol groups can be formed on the unsaturated aliphatic surface of the solid support by contacting the unsaturated aliphatic surface with a polymerization solution containing a free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide.
- a polymerization solution containing a free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide are similar to those used for polymerization of acrylamide monomers (for example, see Perbal, A Practical Guide to Molecular Cloning, 2 nd Edition , (1988), John Wiley & Sons, New York, pages 15-17) and are further described in Example 5 and Example 7.
- the polymerization solution contains a disulfide bisacrylamide in about 0.1% to about 20% in an aqueous solution. If an acrylamide and/or a bisalkylene acrylamide is also present, the concentration of the disulfide bisacrylamide and the acrylamide and/or the bisalkylene acrylamide together is about 0.1% to about 20%.
- an organic solvent such as DMF, can be used to improve reactivity and/or solubility.
- the polymerization reaction is initiated by a free radical initiator.
- a free radical initiator is a substance which decomposes to form a free radical.
- Typical free radical initiators include ammonium persulfate, peroxides, and azo compounds such as azobisisobytyronitrile.
- Ammonium persulfate is a preferred free radical initiator.
- About 0.1% (weight/volume) to about 10% (weight/volume) of the free radical initiator is added to the polymerization solution either before the solution is in contact with the unsaturated aliphatic surface or after the polymerization solution is in contact with the unsaturated aliphatic surface.
- polymerization of the disulfide bisacrylamide on the surface of the solid support forms a solid support having immobilized disulfide groups which are latent thiol groups.
- the immobilized latent thiol groups can be converted to immobilized thiol groups by contacting the solid support with a disulfide reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP), ⁇ -mercaptoethanol and dithiothreitol.
- TCEP tris(2-carboxyethyl)phosphine hydrochloride
- Comonomers can be added to the BAC for co-polymerization.
- Useful comonomers include for example, acrylamide, bis acrylamide; N,N-dimethyl acrylamide, N-octyl acrylamide, poly(ethylene glycol) (n) dimethacrylate, n 200 or 400, (Catalog # 00096 and 02364 (1998-2000 “Polymers and Monomers” Catalog, Polysciences, Inc, Warrington Pa.)).
- a preferred comonomer is pol(yethylene glycol) 400 monomethyl ether monomethacrylate (P400 mm, Catalog # 16665 (1998-2000 “Polymers and Monomers” Catalog, Polysciences, Inc, Warrington Pa.)).
- comonomers that could be, used are well known to those practiced in the art of polymer science and coatings; (see, e.g, 1998-2000 “Polymers and Monomers” Catalog, Polysciences, Inc, Warrington Pa.) In addition, it is well known that mixtures of three or more comonomers can be mixed to achieve polymers with desired properties. Comonomers can be added in organic solvents. Optionally, an organic solvent, such as DMF can be used improve reactivity and/or solubility.
- a solution of acrylamide and non-symmetrical disulfide acrylamides are prepared together with a crosslinking compound such as bis-acrylamide.
- the mixture is polymerized using ammonium persulfate with TEMED, ultraviolet (UV) light, heat, ionizing radiation or or an equivalent known to those of skill in the art.
- the disulfide bonds are reduced, for example, using TCEP or a thiol exchange reaction with DTT.
- Thin polymer layers can be produced by dipping slides in a polymerizing solution. Thicker gels can be formed between glass plates.
- the solid support is a polymer which has reactive functional groups.
- Reactive functional groups include amines, amides, hydroxyl, carboxylic acid, and halogens.
- a preferred polymeric solid support is a polystyrene which has reactive functional soups.
- Preferred reactive functional groups are amine and hydroxyl groups.
- the solid support is contacted with a compound which has a functional group which can react with the reactive functional group of the polymer to form a double bond and a substituted or unsubstituted alkenyl or at least one ⁇ , ⁇ -unsaturated carbonyl to form a solid support having unsaturated aliphatic groups.
- the reactive functional group when the reactive functional group is a halogen, it can react, for example, with an amine or an alkoxide to form a covalent bond.
- the reactive functional group when the reactive functional group is a carboxylic acid, it can react, for example, with an amine or a hydroxide in the presence of dicyclohexylcarbodiimide.
- the reactive functional group when the reactive functional group is an amine or a hydroxyl group, it can react, for example, with an ester, a carboxylic acid or a halogen to form a covalent bond.
- the solid support has an amine or a hydroxyl reactive group, it is contacted with a compound is represented by Structural Formula VI:
- Y and L are as defined in Structural Formula III, and R 10 is a substituted or unsubstituted alkenyl group or a group having at least one ⁇ , ⁇ -unsaturated carbonyl.
- the immobilized unsaturated aliphatic groups are then contacted with a polymerization solution containing a free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide to form a solid support having immobilized latent thiol groups in an acrylamide gel.
- the latent thiol groups can be activated by contacting the gel with a disulfide reducing agent.
- the polymeric solid support which is functionalized with an amine or hydroxyl reactive functional groups is reacted with a compound represented by Structural Formula III to form a solid support having immobilized latent thiol groups.
- the solid support is preferably, cellulose, celite, poly(acrylic acid), polystyrene, cross-linked polystyrene, an agarose or cross-linked agarose, such as Sepharose or Superose, a cross-linked dextran, such as Sephadex or Sephacryl, or a composite of cross-linked agarose and dextran, such as Superdex.
- the latent thiol groups are activated by removing the thiol protecting groups.
- the solid support is silica, alumina, quartz or glass, and the solid support is derivatized with a latent thiol group by contacting the solid support with a compound which has a silane group or a carboxylic acid group and a latent thiol group.
- the compound can be represented by Structural Formula VII:
- R 4 and L are defined as above, and Z is a carboxylic acid group or a silane group of the formula:
- R 11 , R 12 and R 13 are each, independently, a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic group or a substituted or aralkyl group, provided that at least one of R 11 , R 12 or R 13 is a halogen.
- “ ⁇ ” represents the attachment of the silane group to the linking group represented by “L”.
- the solid support is platinum or palladium, and the solid support is derivatized with a latent thiol group by contacting the solid support with a compound that has a nitrile or an isonitrile group and a latent thiol group.
- the compound can be represented by Structural Formula VIII:
- R 4 and L are defined as above, and Z 1 is a nitrile or an isontrile group.
- the solid support is copper and the solid support is derivatized with a latent thiol group by contacting the solid support with a compound that has a hydroxamic acid group and a latent thiol group.
- the nucleic acids can be immobilized on the surface of the support in any pattern or arrangement, e.g., blocks, lines, grids or whorls. Nucleic acids with identical nucleotide sequences can be immobilized on the solid support, nucleic acids with non-identical or different nucleotide sequences can be immobilized on the solid support, and combinations of nucleic acids which contain some portion with identical nucleotide sequences and some portions which contain non-identical sequences can be immobilized on the surface of the solid support.
- a plurality of nucleic acids are attached to the solid support in a manner such that nucleic acids with non-identical nucleotide sequences are found on spatially distinct regions of the surface.
- spatially distinct region is intended to include a region on the surface of a solid support around which an imaginary perimeter can be drawn which does not overlap with the perimeter of any other region.
- array is intended to include a solid support containing nucleic acids immobilized on at least one spatially distinct region of its surface.
- An array can contain any number of nucleic acids immobilized within any number of spacially distinct regions.
- the spacing and orientation of the nucleic acids can be regular, e.g., in a rectangular or hexagonal grid, or the pattern can be irregular or random.
- nucleic acids containing non-identical nucleotide sequences are arranged in a regular pattern on the surface of a solid support. Such an embodiment is particularly useful, for example, in determining whether a particular set of components are present in a sample.
- Nucleic acids capable of detecting the presence of each component of the set can be placed in a spacially distinct region, so that in a single analysis, a determination can be made as to whether one or more of the components of the set are contained within the sample.
- the term “microarray” is intended to include an array in which the spacially distinct regions containing nucleic acids are relatively small.
- An affinity ligand having a thiol reactive group may be contacted with a solid support having free diols either by immersing the solid support in a solution of ligand, or by contacting a drop of ligand to the support.
- the ligand may be deposited by mechanical contact, as with a metal pin, or the ligand may be sprayed, as with a piezoelectric dispenser.
- the volume of solution containing the ligand will vary, depending on the conditions used. For example, with the Affymetrix Model 417 pin-loop spotter, the volume deposited depends on the diameter of the loop (see S. Rose, “Applications of a Novel Microarraying System in Genomics Research and Drug Discovery, Journal of Association for Laboratory Automation, 3:(3) 1998) and is in the range of nanoliters (nL) to picoliters (pL).
- test sample or “test sample” are intended to include component mixtures which can contain the target molecule.
- the test sample can be used directly as obtained from the source or following pretreatment.
- the test sample can be derived from any biological source, such as a physiological fluid, including, blood, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, peritoneal fluid, amniotic fluid and the like, and fermentation broths, cell cultures, and chemical reaction mixtures and the like.
- the test sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, and the addition of reagents.
- a solid material such as cells which can contain the target molecule can be used as the test sample. In some instances, it may be beneficial to modify a solid test sample to form a liquid medium or to release a target molecule.
- the solid supports formed by the methods of the invention can be utilized in a variety of assays.
- assays include a hybridization reaction between the immobilized nucleic acid and a target molecule introduced to the solid support, e.g., contained in a test sample. It is clear to one of skill in the art that such methods can be carried out under a range of hybridization conditions utilizing wash conditions with low to high stringencies. Conditions can be selected based on the amount of similarity or differences between the nucleic acids.
- “Stringency conditions” for hybridization is a term of art which refers to the conditions of temperature and buffer concentration (ionic strength) which permit hybridization of a particular nucleic acid to a second nucleic acid in which the first nucleic acid may be perfectly complementary to the second, or the first and second may share some degree of complementarity which is less than perfect.
- certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity.
- “High stringency conditions” and “moderate stringency conditions” for nucleic acid hybridizations are explained on pages 2.10.1-2.10.16 (see particularly 2.10.8-11) and pages 6.3.1-6 in Current Protocols in Molecular Biology (Ausubel, F. M.
- hybridization conditions By varying hybridization conditions from a level of stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which will allow a given sequence to hybridize (e.g., selectively) with the most similar sequences in the sample can be determined. Binding conditions for triplexes and tetraplexes can be estimated in a similar manner.
- a general description of stringency for hybridization and wash conditions is provided by Ausubel, F. M. et al., Current Protocols in Molecular Biology , Greene Publishing Assoc. and Wiley-Interscience 1987, & Supp. 49, 2000, the teachings of which are incorporated herein by reference.
- nucleotide sequences which are substantially complementary are intended to include nucleic acid sequences which are sufficiently complementary to hybridize with each other under specified conditions.
- complementary nucleic acids contain at least one complementary subsequence.
- sequence is intended to include any contiguous segment of a larger sequence.
- a complementary subsequence includes at least one contiguous segment complementary to the nucleotide sequence of another nucleic acid.
- Target molecules separated or detected in the assays of the invention can be amplified.
- the term “amplified” is intended to include primer dependent nucleic acid synthesis catalyzed by a nucleic acid polymerase.
- the polymerase chain reaction or hereinafter “PCR” can be utilized to amplify a target molecule.
- the method can be used in an assay for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
- kits can contain various components.
- a kit can contain a solid support containing a plurality of latent thiol groups.
- Such a kit can be provided with instructions teaching the purchaser methods for activating the latent thiol groups and for forming a covalent bond between the activated thiol groups and nucleic acids containing an appropriate acrylamide functional group.
- nucleic acids can be synthesized by the purchaser or, alternatively, they can be purchased separately from the kit of the invention.
- Kits containing components in addition to a solid support containing immobilized thiol groups are also within the scope of the invention.
- kits can contain components for activating the thiol groups, e.g. reducing agents and/or a wash buffer.
- Such kits can also contain nucleic acids with acrylamide functional groups.
- the nucleic acids can be identical, non-identical or a combination can be provided.
- components of the kits are contained in separate containers.
- kits can contain a solid support containing a plurality of latent thiol groups and nucleic acids containing an appropriate acrylamide functional group.
- Kits containing components in addition to a solid support containing immobilized thiol groups and nucleic acids containing an appropriate acrylamide functional group are also within the scope of the invention.
- Such kits can contain components for activating the thiol groups, e.g., reducing agents and/or a wash buffer. Typically, components of the kits are contained in separate containers.
- FIG. 1 depicts schematically one method for covalently bonding acrylamide functional nucleic acids to a polystyrene support.
- Step 1 the formation of latent thiol groups on amino-functional polystyrene is illustrated.
- the amino-functional polystyrene microspheres had a diameter of approximately 1 ⁇ m and an amino group density of approximately 75 ⁇ eq/g (Bang's Laboratories Inc., Fisher, Ind.).
- SATP N-succinimidyl S-acetylthioipropionate
- DMSO dimethyl sulfoxide
- the latent thiol derivatized microspheres also referred to as thiolated microspheres, can optionally be dried and stored at this point for future use. If dried, the thiolated microspheres can be rehydrated in phosphate buffer prior to continuing with Step 2.
- the following steps were performed to provide oligonucleotide functional polystyrene microspheres.
- Step 2 the activation of latent thiol (deacetylation) was described.
- Deacetylation buffer was prepared containing 50 mM phosphate buffer, 25 ⁇ M EDTA and 0.5 M of hydroxylamine HCl. It had a final pH of 7.5.
- 100 ⁇ l of the deacetylation buffer was added to the latent thiol microspheres in the centrifuge tube from Step 1. The centrifuge tube was gently shaken for two (2) hours at ambient temperature. After centrifugation, the supernatant and microspheres were separated by decantation providing activated microspheres in the tube.
- Step 3 describes oligonucleotide attachment.
- 100 ⁇ l of 1X TE buffer were added, along with 1.0 ⁇ l of acrylamide-modified oligonuleotide primer pair solution having a concentration of 100 ⁇ M for each oligonucleotide (Operon Technologies, Alameda, Calif.).
- the microsphere suspension was then gently shaken for one (1) hour at ambient temperature.
- Oligonucleotides covalently bound through a thioether linkage to activated microspheres were obtained.
- Step 4 an optional step of blocking the excess reactive thiol groups is described. Excess thiol groups on the oligonucleotide bound microspheres can be blocked, if desired.
- 277 ⁇ g of iodoacetamide Aldrich Chemical Co., Milwaukee, Wis.
- TE buffer 1X 10 mM Tris-HCL pH 8.3; 1 mM EDTA buffer
- the microspheres were washed three (3) times with 100 ⁇ l each of TE buffer to provide capped, oligonucleotide bound microspheres.
- the capped oligonucleotide bound microspheres in the tube were ready for use in a PCR reaction, for example, as illustrated in U.S. Pat. No. 4,683,202, the disclosure of which is incorporated herein by reference.
- the capped oligonucleotide microspheres can be dried and stored at this point for future use. If dried, the capped oligonucleotide microspheres can be rehydrated in phosphate buffer prior to use.
- a glass slide having a plurality of amine groups attached in a substantially uniform spatial pattern to a flat surface thereof (Part #S 4651, aminoalkyl silane coated slides, Sigma Chemical Co., St. Louis, Mo., 1999 catalog) was submerged for two (2) hours at ambient temperature in a solution of 15 mM SATP in 50 mM phosphate buffer pH 7.5, 10% DMSO. The glass slide was then washed three (3) times with 50 mM, pH 7.5 phosphate buffer by submerging the glass slide in phosphate buffer. A glass slide having a plurality of latent thiolated groups was formed.
- the glass slide was submerged in a solution of deacetylation buffer which contains 50 mM of phosphate buffer pH 7.5, 25 ⁇ M of EDTA and 0.5 M of hydroxylamine-HCl, for two (2) hours at ambient temperature to provide a glass slide having a plurality of activated thiol groups.
- a plurality of acrylamide-modified oligonucleotides were attached to the activated thiol groups.
- a lass slide was uniformly modified with acrylamide-modified nucleic acids by submerging the activated glass slide in a 100 ⁇ M solution of acrylamide-modified oligonucleotide in 1X TE buffer (AcryditeTM acrylamide-modified oligonucleotide obtained from Operon Technologies, Alameda, Calif.) for one (1) hour at ambient temperature.
- a capillary dispenser for example, one as illustrated in U.S. Pat. No. 5,807,522, the teachings of which are incorporated herein by reference, can be used.
- Other spotting methods known to those skilled in the art, which permit the regions of the array to be arranged so that the oligonucleotide sequences are appropriately spaced, can also be used.
- random arrays are formed using an ink-jet spray apparatus such as, for example, the apparatus illustrated in U.S. Pat. No. 5,599,695, the teachings of which are incorporated by reference in their entirety.
- regions of an array can be defined utilizing a mask, such as those utilized in photolithography.
- Deacetylation buffer which contains 25 ⁇ M EDTA, 0.5 M hydroxylamine-HCl in 50 mM phosphate buffer is prepared with a final pH of 7.5. It is mixed with 100 mM acrylamide-modified oligonucleotides (Operon Technologies, Alameda, Calif.) in 1X TE buffer. The solution is selectively spotted onto the latent thiol sites in predefined regions. Since only selected areas on the support are provided with activated thiol groups through contact with the deacetylation buffer, only those regions are available for binding acrylamide-modified oligonucleotides. Thus, latent regions remain and can be used to separate the regions to which oligonucleode has been covalently bound.
- a glass slide can be provided with amine groups in a predefined pattern.
- the amine groups can then be converted to latent thiol groups and the support treated as described in Example 2.
- This example demonstrates attachment of acrylamide-modified oligonucleotide probes to a crosslinked polyacrylamide gel support containing the disulfide bisacrylamide crosslinker N,N′-bis(acryloyl)cystamine, (hereinafter “BAC”, Fluka, Buchs, Switzerland).
- BAC disulfide bisacrylamide crosslinker N,N′-bis(acryloyl)cystamine
- Acrylamide groups on the oligonucleotide probes were added during synthesis using commercially available acrylamide phosphoramidites (AcryditeTM phosphoramidites I and III, Mosaic Technologies, Waltham, Mass.).
- FIG. 2B shows that 5′-acrylamide probe binding was prevented by pretreating the TCEP-treated slide with excess monomer acrylamide, suggesting that the acrylamide function of the probes are important for binding.
- FIG. 2A also demonstrates that 5′ amino 230 and 5′hydroxyl 240 modified oligonucleotide probes show low binding to gels containing activated thiol groups.
- Step 1 Preparation of Acrylate Slide Bound to Acrylamide Gel Layer
- Aqueous acrylamide solution was prepared using 6% acrylamide (29:1 ratio of acrylamide monomer to bisacrylamide (BioRad laboratories, Inc.; Hercules, Calif.) and 0.5% (wt/v) N,N′-bis(acryloyl)cystamine (Fluka, Buchs, Switzerland)) in 100 mM sodium borate buffer pH 9 hereinafter “SBB”).
- SBB sodium borate buffer pH 9
- a 100 ⁇ l aliquot was mixed with 1 ⁇ l fresh 10% ammonium persulfate (hereinafter “APS”, BioRad Laboratories, Inc., Hercules, Calif.) and 1 ⁇ l N,N,N′,N′-tetramethyl-ethylenediamine (hereinafter “TEMED”; BioRad, Hercules, Calif.) diluted 10:1 with water to provide an acrylamide gel solution.
- APS fresh 10% ammonium persulfate
- TEMED N,N,N′,N′-tetramethyl-ethylenediamine
- the acrylamide gel solution was overlaid with a glass coverslip (24 ⁇ 50 mm) taking care not to create any air bubbles or gaps.
- the acrylamide gel solution was allowed to polymerize on the acrylate slide for at least 45 minutes at room temperature.
- the coverslip was removed leaving an acrylamide gel layer having latent thiol groups bound to the acrylate slide.
- the slides can be also be dried and stored for later use after rehydration.
- Step 2 Activation of the Latent Thio Groups
- the acrylate slides each having a thio-derivatized acrylamide gel layer were placed in 20 mM TCEP (Fluka; Buchs, Switzerland) in 100 mM SBB pH 9 and were incubated for 15 minutes.
- Step 4 Oligonucleotide Detection By Hybridization
- the slide is imaged dry in a fluorescent imager (Molecular Dynamics, Fluorimager 595, Sunnyvale, Calif.).
- Step 1 Preparation of Gel-Coated Slide Supports
- a polymerization solution was prepared with 6% acrylamide (29:1), and 0.5% BAC (wt/v), in 100 mM SBB pH9. (BAC required heating and vortexing to go into solution). 1 ⁇ l fresh 10% APS (made same day) and 1 ⁇ l of 10:1 dilution of H 2 O:TEMED were added to 100 ⁇ l of the solution and mixed thoroughly. 10 ⁇ l of solution were pipetted onto an Acrylate Slide (CEL Associates, Inc., ACR-25C) and overlaid with a lass overslip (18 ⁇ 18 mm), taking care not to create any air bubbles or gaps in the solution. The acrylamide layer was allowed to polymerize at least 20 minutes at room temperature. After the slides were rinsed in TE and allowed to air dry, they were ready for spotting of oligo.
- Step 2 Activation of the Latent Thiol Group
- the slides were incubated on a lab bench at room temperature for one (1) hour. After one (1) hour, the slides were soaked for 30 minutes in 20% dimethylacrylamide (hereinafter “DMA”) or 20% 2-hydroxyethylmethacrylate (hereinafter “HEMA”) in 100 mM SBB at pH 9. The slides were washed two (2) times with TE+0.2M NaCl. Then, the slides were washed once in TE and allowed to dry.
- DMA dimethylacrylamide
- HEMA 2-hydroxyethylmethacrylate
- Step 4 Oligonucleotide Detection by Hybridization
- Adhesive hybridization chambers were attached to the slides and 90 ⁇ l of the hybridization mixture were added to slides: cDNA prepared from 50 ng input globin RNA in 4X SSPE+0.2% Tween. The slides were hybridized overnight at 55° C. in a humid hybridization chamber. After incubation, the slides were washed two (2) times with 1XSSPE+0.1% Tween. Then, the slides were washed one (1) time with TE and allowed to air dry. The slides were imaged dry.
- DMF dimethyl formamide
- 123 mg of AEMA were dissolved in 0.5 ml dimethyl formamide (hereinafter “DMF”) and 1.5 ml water. After the AEMA was dissolved the following was added: Final conc: 1.5 ml 40% stock acrylamide/bis solution 6.0% (844 mM) 2.0 ml 500 mM Tris-Glycine buffer pH 9.0 100 mM 5.0 ml water 10 ml total
- a series of solutions of 50 ⁇ l volume was prepared for spotting on slides.
- the solutions contained different concentrations (3, 10 and 30 mM) of AcryditeTM-modified DNA olionucleotide BD 1216 (complementary probe for rabbit globin cDNA target) in either 100 mM Tris-Glycine pH 9 or 100 mM sodium carbonate pH 10 buffer.
- solutions containing 10 mM oligo and 10% or 20% glycerol were prepared. (Glycerol containing solutions are less sensitive to humidity of air during spotting and give higher yields of DNA probes binding in low and moderate humidity)
- all gel solutions were reduced with TCEP before spotting and no TCEP was added into spotting solutions.
- Hybridization was carried out overnight at 55° C. in plastic chambers with rabbit globin cDNA labeled with Cy3 fluorescent dye. Concentration of cDNA was 50 ng/ml of hybridization buffer (4X SSPE containing 0.02% Tween 20). After hybridization, the slides were washed three (3) times in 1X SSPE buffer and briefly washed two (2) times in 10 mM TE buffer, then dried using nitrogen.
- hybridization buffer (4X SSPE containing 0.02% Tween 20
- the arrays were scanned with ScanArray 4000 scanner (GSI Lumonics, Watertown, Mass.) using green line 543.5 nm of HeNe laser for excitation.
- the laser power was set at 90% and photomultiplier power (PMT) was set at 60%.
- the data was analyzed using ImageQuant 5.1 software (Molecular Dynamics, Sunnyvale, Calif.). The background signal from an unspotted position on the microarray was subtracted from the total fluorescence signal of each hybridized probe spot.
- FIGS. 6 and 7 The corrected fluorescence intensity data are plotted in FIGS. 6 and 7.
- FIG. 7 compares the Tris-Glycine buffer with the carbonate buffer. At each concentration of probe oligonucleotide tested, better hybridization signals were obtained when the probes were spotted with the carbonate buffer system.
- FIG. 7 shows data only for the 10 ⁇ M probe spots.
- the enhancement may result from the fact that BAC derived thiols in gels cast with unreduced BAC, as in the BAC protocol of Example 7, may be held in close proximity after reduction in the gel, and therefore may reform the disulfide, thereby reducing the number of thiol groups available for probe binding.
- cDNA prepared from rabbit reticulocyte polyA+mRNA (Gibco-BRL; Life Technologies; Rockville, Md.) with an arrayTRACKERTM Standard Labeling cDNA Kit (Cat. #490-100, Displays Systems Biotech, Inc.; Vista, Calif.) in accordance with the instructions provided with the kit using the following modification: After the final precipitation in the display systems protocol, the cDNA preparation was resuspended in 40 ⁇ L buffer (4X SSPE; 0.02% Tween20®), and this mixture was run through a G25 spin column (Cat. # 27-5325-01 Amersham Pharmacia, Microspin G-25 column).
- the hybridized spotted slide was washed three (3) times in 1X SSPE buffer containing 0.02% Tween20®, then in TE, and then dried with a stream of nitrogen.
- the hybridized oligonucleotide spotted slide was imaged with a GSI Lumonics ScanArray 4000 Microarray Analysis System (GSI Lumonics, Inc.; Billerica, Mass.).
- Example 7 A procedure similar to that in Example 7 was used to make slides with 2% BAC, with various amounts of P400 mm.
- four acrylate slides were immersed in a solution made by mixing: 3.6 ml of 10% BAC in DNEF, 5.4 ml of DMF; 9 ml of water; 180 ⁇ L of P400 mm; 240 ⁇ L of 25% APS; 40 ⁇ L TEMED After standing at room temperature, the appearance of the solution was noted.
- the BAC acrylate slides were then removed from the solution and rinsed in deionized water. In cases where a film was visible on the slides, gentle rubbing was used to remove the visible white film.
- the BAC acrylate slides were again washed in water, and then dried with a stream of nitrogen.
- cDNA prepared from rabbit reticulocyte polyA+mRNA (Gibco-BRL; Life Technologies, Rockville, Md.) with an arrayTRACKERTM Standard Labeling cDNA Kit, (Cat. #490-100, Displays Systems Biotech, Inc.; Vista, Calif.) in accordance with the instructions provided with the kit, except that after the final precipitation in the display systems protocol, the cDNA preparation was resuspended in 40 ⁇ L of buffer (4X SSPE; 0.02% Tween20®), and this mixture was run through a G25 spin column (Cat. #27-5325-01, Amersham Pharmacia, Microspin G-25 column).
- the hybridized spotted slide was washed three (3) times in 1X SSPE buffer containing 0.02% Tween20®, then in TE, and then dried with a stream of nitrogen.
- the hybridized oligonucleotide spotted slide was imaged with a GSI Lumonics ScanArrayR 4000 Microarray Analysis System (GSI Lumonics, Inc.; Billerica, Mass.).
- S-B signal minu the signal for spot with 0 oligo.
- FIG. 4 shows a plot of fluorescent intensity across a spot for slides prepared with 2% BAC or 2% BAC plus P400 mm at the different concentrations.
- 1% BAC in water coated slides were prepared as follows: 0.5 g of BAC was dissolved in 50 ml of deionized water at 70° C. Acrylate slides were completely submerged in the heated BAC solution. 1.0 ml of 0.05% APS and 1.0 ml of 0.05% TEMED were added The container was sealed and shaken for 1 minute. The polymerization reaction was complete within several minutes. A white precipitate of polyBAC formed. After removal of the macroscopic polyBAC particulate with water, the acrylate slides appeared coated with a homogeneous thin white film. This film was removed by gentle scrubbing under water. The resulting dried BAC acrylate slides appeared clear and transparent with no visible residue.
- a BAC acrylate slide was then spotted with different concentrations ranging from 30 ⁇ M to 1 ⁇ M of beta-globin-specific 70mer AcryditeTM modified oligonucleotide containing TCEP in the spotting solution.
- the spots were visualized by hybridization with Cy3 labeled globin cDNA (10 ng/80 ul) in 100 ⁇ l of 20 ⁇ saline sodium phosphate EDTA buffer (SSPE; 3.6 M sodium chloride, 200 mM sodium phosphate, pH 7.4, 20 mM EDTA, pH 7.4) in a hybridization chamber.
- the visualized spots formed are shown in FIG. 5, a photograph of the BAC acrylate slide after hybridization to a fluorescent complementary oligonucleotide probe.
- a piece of nylon screen is placed between two silane treated glass plates. An edge of the nylon screen is allowed to extend from between the plates. A measured aliquot of the gel solution from Example 5 is placed on the extension and the solution is wicked onto the nylon screen between the two glass plates. The solution is allowed to gel. Prior to use the slide is activated and provided with AcryditeTM modified oligonucleotides as above.
- a polyacrylamide gel matrix wherein the polyacrylamide matrix has dithiol cross-linkages (no nucleic acid or protein probes) such as, for example, by following Example 5, Step 1.
- the reagents for forming the thiol-derivatized acrylamide gel solution mix in a desired cell type for culture.
- E. coli provided with nutrient culture reagents may be grown within the polymerized gel.
- cleave the dithiols to the degree desired, for example by following the procedure described in Example 5, step 2 to release the cells.
- Step 1 using a bisacrylamide cross-linker with bound AcryditeTM modified oligonucleotides having a desired primer sequence to provide a thiol derivatized acrylamide gel solution additionally having bound oligonucleotides.
- the reagents to include a second primer in solution where desired; nucleic acids; enzyme
- Cleave the latent thiol groups using a procedure such as that described in Example 5, Step 2. Release and remove the amplified nucleic acid.
- the white particulate can be removed from the slides under water by a gentle hand scrub. Slides were suspended in 5-100 mM TCEP for reduction of disulfides. Thiol formation was immediately evident by development of a putrid odor. The slides were then dried for spotting.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
A method is provided for immobilizing a ligand, e.g., a nucleic acid, on a solid support. The method includes providing a solid support containing an immobilized latent thiol group, activating the thiol group, contacting the activated thiol group with a nucleic acid comprising an acrylamide functional group, and forming a covalent bond between the two groups, thereby immobilizing the nucleic acid to the solid support. Kits containing the solid supports and method of utilizing the solid supports are also provided.
Description
- This application claims the benefit of the Provisional Application with Serial No. 60/151,267 filed Aug. 27, 1999 and the Provisional Application with Serial No. 60/177,844 filed Jan. 25, 2000. The teachings of both cited applications are incorporated herein by reference in their entireties.
- A variety of assay systems utilize ligands, e.g., nucleic acids, immobilized on the surface of a solid support. Effective immobilization of the nucleic acids is difficult, both because a range of materials are used to form the solid supports utilized in these assays, and because individual assays have special requirements. Therefore, although a number of attachment mechanisms have been developed, none are universally acceptable and most exhibit notable deficiencies. Among other drawbacks, present methods tend to require large amounts of nucleic acids, have high background noise levels or lack versatility (Duran et al. U.S. Pat. No. 5,858,653 issued Jan. 12, 1999).
- The reproducible production of solid supports containing immobilized nucleic acids can also be problematic. For example, a convenient method of attachment utilizes nucleic acids with acrylamide functional groups which can be copolymerized to polyacrylamide gel matrices by free radical polymerization. However, oxidation can affect the copolymerization process resulting in variability in the results achieved using different supports, even when prepared using the same materials. Moreover, long-term stability of supports containing immobilized ligands has been difficult to achieve, often limiting the period of use to shortly after preparation.
- The present invention is based, at least in part, on the discovery of a novel and convenient method of mobilizing a ligand, e.g., a nucleic acid, on a solid support. The method utilizes a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on the nucleic acid to immobilize the nucleic acid to the support. In a particular embodiment, the covalent bond formed is a sulfide, a thioether, bond. The solid support can contain a polymer layer.
- The method and the supports it produces are advantageous in several respects. The method utilizes reagents which are both readily available and compatible with the types of analysis conducted with solid supports. Because the materials can be used in aqueous solutions, the need for special skills and sophisticated chemical apparatus are minimized. In addition, because the materials and the supports they form are quite stable, the reproducibility from support to support which has previously proved so difficult to achieve can be realized. This stability also permits the components forming the bond to be combined at different times. For example, because solid supports containing the latent thiol groups of the invention are extremely stable, they can be produced under consistent conditions for use at a later time. Prior to analysis, the latent thiol groups can be activated and contacted with the acrylamide modified nucleic acids to form a support containing immobilized nucleic acids. In a particular embodiment, the thiol groups are activated by contact with a reducing agent.
- In one embodiment, the invention is directed to a method of immobilizing an affinity ligand on a solid support comprising providing a solid support comprising an immobilized thiol group, contacting the thiol group with a nucleic acid comprising an acrylamide functional group, and forming a covalent bond between the two groups, thereby immobilizing the ligand on the solid support.
- In a particular embodiment; the ligand is a nucleic acid, a modified nucleic acid or a nucleic acid analog. The solid support can comprise a plurality of thiol groups. A plurality of ligands can be immobilized on the solid support. In alternate embodiments, the solid support is formed from glass, silica, ceramic, plastic or metal compounds. The solid support can comprises two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids. The solid support can further comprise a polymer layer. In a particular embodiment, the solid support can comprise a microarray. The thiol groups can comprise disulfide groups.
- In another embodiment, the invention is directed to a method of immobilizing an affinity ligand on a solid support comprising the steps of providing a solid support comprising immobilized latent thiol groups, activating the latent thiol groups, and reacting the activated thiol groups with an affinity ligand having at least one acrylamide functional group, thereby immobilizing an affinity ligand on a solid support.
- In a particular embodiment, the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog. The steps of activating the latent thiol groups and reacting the activated thiol groups can occur essentially simultaneously. In alternate embodiments, the solid support is formed from glass, ceramic, plastic and metal. The solid support can comprise two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids. The solid support can further comprises a polymer layer. The solid support can comprise a microarray.
- In another aspect, the invention is directed to the product formed by the method of forming a solid support described above.
- In another embodiment, the invention is directed to a method of immobilizing an affinity ligand on microarray comprising the steps of providing a solid support comprising immobilized latent thiol groups, activating the latent thiol groups, and reacting the activated thiol groups with an affinity ligand having at least one α,β unsaturated carbonyl functional group, thereby immobilizing an affinity ligand on a solid support. In a particular embodiment, the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog. The steps of activating the latent thiol groups and reacting the activated thiol groups canoccur essentially simultaneously.
- In another embodiment, the invention is directed to a method of immobilizing an affinity ligand on microarray comprising the steps of providing a solid support comprising immobilized latent thiol groups, the latent thiol groups and reacting the activated thiol groups with an affinity ligand having at least one α,β unsaturated carbonyl functional group, thereby immobilizing an affinity ligand on a solid support. In a particular embodiment, the ligand is a nucleic acid, a modified nucleic acid or a nucleic acid analog. The steps of activating the latent thiol groups and reacting the activated thiol groups can occur essentially simultaneously.
-
- In Structural Formula I, X is a halogen, and R 1, R2 and R3 are each, independently, a halogen, an alkyl group, an alkenyl group or a group having at least one α,β-unsaturated carbonyl, provided that at least one of R1, R2 or R3 is an alkenyl group or a group having at least one α,β-unsaturated carbonyl. The unsaturated aliphatic surface is then contacted with a polymerization solution containing free radical initiator, a disulfide bisacrylamide, and optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups. Disulfide bisacrylamides can be represented by Structural Formula IIA:
- In Structural Formula IIA, n and m are each, independently, a positive integer.
- The latent thiol groups can be activated by contacting the solid support with a disulfide reducing agent. When it is desirable to have a crosslinked gel having immobilized thiol groups, the polymerization solution can additionally include alkylene bisacrylatide.
- In an alternative embodiment, the unsaturated aliphatic surface is then contacted with a polymerization solution containing free radical initiator, a compound having a α,β-unsaturated carbonyl and a protected thiol group, and optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups. The compound having an α,β-unsaturated carbonyl and a protected thiol group preferably can be represented by Structural Formulas IIB-IID:
- In Structural Formulas IIB-IID, R 11 and R4 are defined as above. R14 is —(CH2)p- or —(OCH2CH2)p-. In a preferred embodiment, R4 is —SR15, wherein R15 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted aralkyl group.
- In several embodiments of the invention, it is useful to provide latent thiol groups through the use of polymerizable disulfide compounds. As indicated in Structures IIB-D, such compounds can be monofunctional or bifunctional with regard to the α,β unsaturated carbonyl group. A commercially available example of a bifunctional disulfide reagent is BAC. An example of a monofunctional disulfide reagent is AEMA (Schnaar, R. L. et al., 1985, Analytical Biochemistry, 151:268-281). Additional monofunctional acrylamide disulfide derivatives can be generated by reacting BAC with the reducting agents β-mercaptoethanol and thioacetic acid, as shown if FIGS. 8 and 9.
- In a particular embodiment, the free radical initiator is added to the polymerization solution after the solution is in contact with the unsaturated aliphatic surface of the solid support.
- The method can additionally include derivatizing the solid support with a latent thiol group, thereby forming a solid support having immobilized latent thiol groups. In a particular embodiment, the solid support includes an amine functional group and the solid support is derivatized by contacting the solid support with a compound represented by Structural Formula III:
- In Structural Formula III, Y is a leaving group, L is a linking group, and R 4 is a thiol protecting group. The derivatized solid support formed has immobilized latent thiol groups.
-
- wherein R 6 and R7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
-
- wherein R 8 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- In another aspect, the invention is directed to a method of preparing a solid support having immobilized thiol groups. The method includes contacting a glass solid support with a silane compound represented by Structural Formula I to form a solid support having an unsaturated aliphatic surface. The unsaturated aliphatic surface of the solid support is then contacted with a polymerization solution containing free radical initiator, a disulfide bisacrylamide represented by Structural Formula IIA-D, and optionally containing an acrylamide to form a solid support comprising immobilized latent thiol groups. The latent thiol groups of the solid support are then contacted with a disulfide reducing agent to form a solid support having immobilized thiol groups.
- In one embodiment, the solid support is doped or undoped silica, alumina, quartz or glass, and the method further comprises the steps of contacting the solid support with a compound comprising a silane group or a carboxylic acid and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- wherein n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
-
- wherein X is a halogen, and R 1, R2 and R3 are each, independently, a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, provided that at least one of R1, R2 or R3 is a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl.
- The latent thiol groups can be activated by contacting the solid support with a disulfide reducing agent. The polymerization solution can further include alkylene bisacrylamide. The free radical initiator can be added to the polymerization solution after the solution is in contact with the unsaturated aliphatic surface of the solid support
- The solid support can be gold, silver, copper, cadmium, zinc, palladium, platinum, mercury, lead, iron, chromium, manganese, tungsten, and alloys thereof, and the method can further comprises the steps of contacting the solid support with a compound comprising a thiol group, sulfide or disulfide group and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing a conmonomer, wherein the disulfide bisacrylamide is represented by the following structural formula:
- whereinn and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- The solid support can be platinum or palladium, and the method can further comprises the steps of contacting the solid support with a compound comprising a nitrile or isonitrile group and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- wherein n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- The solid support can be copper, and the method can further comprise the steps of contacting the solid support with a compound comprising a hydroxamic acid group and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, and contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator and disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- wherein n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
- The solid support can be a polymer comprising a reactive functional group, and the method can further comprise the steps of contacting the solid support with a compound comprising a functional group which can react to form a bond with the reactive functional group and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having immobilized unsaturated aliphatic group, and contacting the unsaturated aliphatic groups of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- wherein n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
-
-
- wherein R 6 and R7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
- The method can further comprise the step of derivatizing a solid support with a latent thiol group, thereby forming a solid support having immobilized latent thiol groups. The solid support can be doped or undoped silica, alumina, quartz or glass, and the solid support can be derivatized by contacting it with a compound comprising a silane group or a carboxylic acid group and a latent thiol group.
- The solid support can be platinum or palladium, and the solid support is derivatized by contacting it with a compound comprising a nitrile or isonitrile group and a latent thiol group.
- The solid support can be a polymer comprising reactive functional groups, and the solid support is derivatized by contacting it with a compound comprising a functional group which can react to form a bond with the reactive functional group and a latent thiol group. The polymeric solid support can be polystyrene. The reactive functional group of the polymeric solid support can be an amine or a hydroxyl group and the solid support can be derivatized by contacting the solid support with a compound represented by the following structural formula:
-
- wherein R 6 and R7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group. R4 can be:
- wherein R 6 is a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
-
- whereinX is a halogen, and R 1, R2 and R3 are each, independently, a halogen, an alkyl group, an alkenyl group or a group having at least one α,β-unsaturated carbonyl, provided that at least one of R1, R2 or R3 is an alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface, contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
- wherein n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups, and contacting the latent thiol groups with a disulfide reducing agent, thereby forming a solid support having immobilized thiol groups.
- In another embodiment, the invention is directed to a method of forming an array of nucleic acids immobilized on a solid support including forming an amine-derivatized region on the support, treating the amine-derivatized region with a thiolating agent such that latent thiol groups immobilized on the support are formed, activating the latent thiol groups, contacting the activated thiol groups with a plurality of nucleic acids comprising acrylamide functional groups, and forming a covalent bond between the two groups, thereby forming an array of nucleic acids immobilized on the solid support. In alternate embodiments, each nucleic acid contained in the array includes a nucleotide sequence identical to or substantially identical to, the nucleotide sequence of the other nucleic acids of the array, or nucleic acids with a plurality of nucleotide sequences are contained in the array. The solid support can include a plurality of amine-derivatized regions. The method can further include a step of blocking any unbonded reactive thiol groups remaining following the binding of the nucleic acids to the thiol groups.
- In another aspect, the invention is directed to a kit for attaching nucleic acids to a solid support including a solid support component including a plurality of immobilized latent thiol groups and instructions for activating the thiol groups to form covalent bonds with nucleic acids including acrylamide functional groups. Such kits can also include an activator component, an acrylamide functional nucleic acids component, a blocking component and/or a wash buffer.
- In an alternate embodiment, the invention is directed to a kit for attaching nucleic acids to a solid support including a solid support component including a plurality of immobilized latent thiol groups and nucleic acids including acrylamide functional groups. In a particular embodiment, the nucleic acids are immobilized on the solid support by a covalent bond between the immobilized thiol groups and the nucleic acids. Such kits can also include an activator component, a blocking component and/or a wash buffer.
- In another aspect, the invention is directed to a method for detecting or separating target nucleic acids from other components contained in a sample including providing a solid support comprising a plurality of immobilized nucleic acids comprising nucleotide sequences complementary to a subsequence of the nucleotide sequence of the target nucleic acid, wherein the nucleic acids are immobilized by a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on the nucleic acid, contacting the immobilized nucleic acid with the test sample, and hybridizing target nucleic acids to immobilized nucleic acids with complementary subsequences, thereby separating target nucleic acids from other components contained in the sample. After detection or separation, the target nucleic acids can be amplified. The method can be used in an assay for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
- In another embodiment, the invention is directed to a method for detecting or separating target nucleic acids from other components contained in a sample including providing a solid support comprising a plurality of immobilized thiol groups, contacting the thiol groups with a plurality of nucleic acids comprising nucleotide sequences complementary to a subsequence of the nucleotide sequence of the target nucleic acid and acrylamide functional groups, forming a covalent bond between the two groups, thereby immobilizing the nucleic acids on the solid support, contacting the immobilized nucleic acids with the test sample, and hybridizing target nucleic acids to immobilized nucleic acids with complementary subsequences, thereby detecting or separating target nucleic acids from other components contained in the sample. After detection or separation, the target nucleic acids can be amplified. The method can be used in an assay for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
- FIG. 1 is a schematic representation of a method of derivatizing an amine group bearing polystyrene support with an acrylamide derivatized oligonucleotide.
- FIG. 2A is a representation of a solid support selectively treated to activate latent thiol groups.
- FIG. 2B is a representation of a solid support in which reactive groups are blocked, then exposed to acrylamide functional oligonucleotides.
- FIG. 3A is a photograph showing results of microarray formation on a N,N′ bis(acryloyl)cystamine (BAC) coated slide in which excess thiol groups were blocked with dimethylacrylamide (DMA).
- FIG. 3B is a photograph showing results of microarray formation on a N,N′ bis(acryloyl)cystamine (BAC) coated slide in which excess thiol groups were blocked with 2-hydroxymethacrylate (HEMA).
- FIG. 4 is a plot of fluorescent intensity across a spot for slides prepared with 2% N,N′ bis(acryloyl)cystamine (BAC) or 2% N,N′ bis(acryloyl)cystamine(BAC) plus P400 mm.
- FIGS. 5A-5C are photographs showing a N,N′ bis(acryloyl)cystamine (BAC) acrylate slide after hybridization to fluorescent complementary oligonucleotide probes.
- FIG. 6 is a bar graph illustrating the results obtained from a comparison of hybridizations performed using Tris-Glycine buffer and those performed using carbonate buffer.
- FIG. 7 is a bar graph illustrating the results of an experiment showing the influence of buffer and glycerol in spotting solution on hybridization signal for 10 μl probe spots.
- FIG. 8 is a schematic of a synthesis for a non-symmetrical disulfide acrylamide.
- FIG. 9 is a schematic of a synthesis for a non-symmetrical disulfide acrylamide.
- The present invention is based, at least in part, on the discovery of a novel and convenient method of immobilizing an affinity ligand on a solid support. The method utilizes a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on an affinity ligand to immobilize the affinity ligand to the support. In a particular embodiment, the covalent bond formed is a sulfide, a thioether, bond.
- The method and the supports it produces are advantageous in several respects. The method utilizes reagents which are both readily available and compatible with the types of analysis conducted with solid supports. Because the materials can be used in aqueous solutions, the need for special skills and sophisticated chemical apparatus are minimized. In addition, because the materials and the supports they form are quite stable, the reproducibility from support to support which has previously proved so difficult to achieve can be realized. This stability also permits the components forming the bond to be combined at different times. For example, because solid supports containing the latent thiol groups of the invention are extremely stable, they can be produced under consistent conditions for use at a later time. Prior to analysis, the latent thiol groups can be activated and contacted with the acrylamide modified nucleic acids to form a support containing immobilized nucleic acids. In a particular embodiment, the thiol groups are activated by contact with a reducing agent.
- In one embodiment, the method is directed to a method of immobilizing an affinity ligand on a solid support. The method includes providing a solid support comprising an immobilized thiol group, contacting the thiol group with an affinity ligand comprising an acrylamide functional group, and forming a covalent bond between the two groups, thereby immobilizing the affinity ligand on the solid support.
- The term “affinity ligand” is intended to include any molecule that can form a specific binding complex with a target analyte and can be immobilized on a suitable solid support. Any suitable ligand can be used in the present invention provided that it can form a specific binding complex with a target analyte. Methods for determining the thermal stability of binding complexes and, in particular, hybridization complexes are well known in the literature. Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26:227-259 (1991); Quartin and Wetmur, Biochemistry, 28:1040-1047 (1989).
- One especially useful example of an affinity ligand is a single-stranded nucleic acid, which can bind by hybridization, for example, to an analyte that contains a complementary nucleic acid sequence. The single stranded nucleic acid affinity ligand can be complementary to the entire analyte nucleic acid sequence or to a portion thereof. Single-stranded nucleic acids can also be used for isolation of duplex nucleic acids by triplex formation (Hogan and Kessler, U.S. Pat. No. 5,176,966 and Cantor, et al., U.S. Pat. No. 5,482,836, the teachings of which are incorporated herein by reference). Double-stranded nucleic acids can also serve as useful affinity ligands for nucleic acid binding proteins, or for nucleic acid analytes that bind to the ligand by triplex or tetraplex formation. The conditions under which a single stranded nucleic acid will bind to another nucleic acid to be immobilized on a solid support can be estimated by those skilled in the art using the procedure referenced above. In addition, the melting temperature (T m) of the two nucleic acids provides a reasonable framework for estimating the temperate at which an nucleic acid analyte will hybridize to a nucleic acid affinity ligand. In general, the Td is lower than the Tm by about 15 to 25° C. and, therefore, the temperature at which the gel should be run to facilitate specific hybridization between the analyte and affinity ligand should be about 15 to 25° C. or more below the Tm.
- Nucleic acid aptamers (Tuerk and Gold, Science (1990) 249:5050; Joyce, Gene (1989), 82:83-87; Ellington and Szostak, Nature (1990), 346:818-822) can also be used as affinity ligands in the process of the present invention. Aptamers can be selected against many kinds of analytes, including proteins, small organic molecules, and carbohydrates (reviewed in Klug and Famulok, Molecular Biology Reports (1994), 20:97-107). Thus, selection of aptamer ligands offers a simple and flexible mechanism for obtaining affinity ligands against virtually any target molecule.
- Other useful ligands include proteins or polypeptides which can bind to specific analytes. An especially useful class of protein ligands are antibody molecules, which can be elicited against a wide range of analytes by immunization methods. Antibodies ligands can be monoclonal or polyclonal. In addition, a fragment of an antibody can be an affinity ligand. Similarly, receptor proteins may be useful as ligands for purification and detection of analytes that bind to or are bound by them.
- Carbohydrates have been successfully used as affinity ligands for electrophoretic purification of lectins (Horejsi and Kocourek, Biochim. Biophys. Acta (1974), 336:338-343), and may be useful for purification and detection of molecules that bind to specific carbohydrates or glycoproteins.
- Binding or non-binding conditions of proteins, aptamers and lectins for specific ligands can be estimated using the procedure outlined above for estimating the stability of analyte/affinity ligand complexes. In addition, equilibrium dialysis experiments can provide a rational method of predicting the stability of analyte/affinity ligand complexes. For example, the dissociation constant of a protein for a particular ligand can be determined in the electrophoresis buffer at several different pHs, temperatures or ionic strengths. The higher the dissociation constant, the weaker the binding between the protein and the ligand (see Segel, I. H., Biochemical Calculations, 2nd Edition (1976), John Wiley & Sons, New York, p. 241-244). From this data a binding and a non-binding condition can be estimated.
- Many other types of immobilized ligands are possible including peptides, amino acids, nucleosides, small organic molecules, lipids, hormones, drugs, enzyme substrates, enzyme inhibitors, enzymes, coenzymes, inorganic molecules, chelating agents, macromolecular complexes, polysaccharides, monosaccharides, and others.
- In a particular embodiment, a nucleic acid can be utilized as an affinity ligand. Such nucleic acids include deoxyribonucleic acid (hereinafter “DNA”), or ribonucleic acid hereinafter “RNA”), modified nucleic acids, nucleic acid analogs, and chimeric molecules of a mixed class comprising a nucleic acid with another organic component, e.g., peptide nucleic acids. Nucleic acids can be single-stranded or double-stranded nucleic acids. Typically, the length of a nucleic acid will be at least about 5 nucleotides in length, more typically between about 5 and 100 nucleotides even more typically between 5 and 50, although it can be as long as several thousand bases.
- Such nucleic acids are typically “isolated” nucleic acids, e.g., nucleic acids separated away from the components of their source of origin (e.g., as it exists in cells, or in a mixture such as a library) and can have undergone further processing. Isolated nucleic acids include nucleic acids obtained by methods known to those of skill in the art. These isolated nucleic acids include substantially pure nucleic acids, e.g., nucleic acids free from protein, carbohydrate or lipids. Nucleic acids can be produced by chemical synthesis, or by combinations of biological and chemical methods or by recombinant methods.
- The term “modified nucleic acid” is intended to include nucleic acids containing modified bases, deoxyribose groups or phosphates. Examples of nucleic acids having modified bases, include, for example, acetylated, carboxylated or methylated bases e.g, 4-acetylcytidine, 5-carboxymethylaminomethyluridine, 1-methylinosine, norvaline or allo-isoleucine.
- The term “nucleic acid analog” is intended to include molecules that lack a conventional deoxyribose/ribose-phosphodiester backbone, but which retain the ability to form Watson-Crick type base pairs with complementary single-stranded nucleic acids. Examples of nucleic acid analogues include peptide nucleic acids (PNAS; Egholm et al., 1992, J. Am. Chem. Soc. 114: 1895-1897) and morpholino oligomers (morpholinos; Summerton and Weller, Antisense Nucleic Acid Drug Dev., (1997)7:187-195). It will be apparent to those skilled in the art that similar design strategies can be used to construct other nucleic acid analogs that will have useful properties for immobilized probe assays.
- The term “alkyl group”, as used herein, is intended to include straight chained or branched C 1-C18 hydrocarbons which are completely saturated, or cyclic C3-C18 hydrocarbons which are completely saturated. Lower alkyl groups are straight chained or branched C1-C3 hydrocarbons or C3-C8 cyclic hydrocarbons which are completely saturated. Alkyl groups are preferably lower alkyl groups.
- The term “alkenyl group,” as used herein, is intended to include straight chained or branched C 1-C18 hydrocarbons which have one or more double bond, or cyclic C3-C18 hydrocarbons which have one or more unconjugated double bond. Lower alkenyl groups are straight chained or branched C1-C8 hydrocarbons which have one or more double bond or C3-C8 cyclic hydrocarbons which have one or more unconjugated double bond. Alkenyl groups are preferably lower alkenyl groups.
- The term “aromatic group” is intended to include carbocyclic aromatic ring systems (e.g., phenyl) and carbocyclic aromatic ring systems fused to one or more carbocyclic aromatic or non-aromatic ring (e.g., naphthyl, anthracenyl and 1,2,3,4-tetrahydronaphthyl).
- Heteroaromatic groups, as used herein, include heteroaryl ring systems (e.g., thienyl, pyridyl, pyrazole, isoxazolyl, thiadiazolyl, oxadiazolyl, indazolyl, furans, pyrroles, imidazoles, pyrazoles, triazoles, pyrimidines, pyrazines, thiazoles, isoxazoles, isothiazoles, tetrazoles, or oxadiazoles) and heteroaryl ring systems in which a carbocyclic aromatic ring, carbocyclic non-aromatic ring, heteroaryl ring or a heterocycloalkyl ring is fused to one or more other heteroaryl rings (e.g., benzo(b)thienyl, benzimidazole, indole, tetrahydroindole, azaindole, indazole, quinoline, imidazopyridine, purine, pyrrolo[2,3-d]pyrimidine, and pyrazolo [3 ,4-d]pyrimidine).
- The term “aralkyl group,” as used herein, is intended to include aromatic substituents that are linked to a moiety by an alkyl group that preferably has from one to about six carbon atoms.
- The term “heteroaralkyl group,” as used herein, is intended to include heteroaromatic substituents that are linked to a moiety by an alkyl group that preferably has from one to about six carbon atoms.
- The term “heterocycloalkyl group,” as used herein, is intended to include non-aromatic ring systems that preferably has 5 to 6 atoms and include at least one heteroatom, such as nitrogen, oxygen, or sulfur. Examples of heterocycloalkyl groups include morpholines, piperidines, and piperazines.
- Suitable substituents for aliphatic groups, aromatic groups, aralkyl groups, heteroaromatic groups and heterocycloalkyl groups include aromatic groups, halogenated aromatic groups, lower alkyl groups, halogenated lower alkyl (e.g. trifluoromethyl and trichloromethyl), —O-(aliphatic group or substituted aliphatic group), —O-(aromatic group or substituted aromatic group), benzyl, substituted benzyl, halogens, cyano, nitro, —S-(aliphatic or substituted aliphatic group), and —S-(aromatic or substituted aromatic).
- The term “linking group,” as used herein, includes substituted or substituted alkyl groups, substituted or unsubstituted aromatic groups, substituted or unsubstituted aralkyl groups and substituted or unsubstituted polyether groups.
-
- In Structural Formula IV, R 11 is —H, or a substituted or unsubstituted alkyl group. In a preferred embodiment, R11 is a —H or a methyl group.
- An affinity ligand can be derivatized with a selectively thiol reactive group. Such thiol reactive groups can include methacrylate, methacrylamide, α,β unsaturated carbonyl groups [CH2CHC(F2)], α,β unsaturated difluoro groups and maleimide groups. In general, such groups show enhanced reactivity with thiol groups, as opposed to other functional gorups present in the reaction.
- In several embodiments of the invention, it is useful to provide latent thiol groups through the use of polymerizable disulfide compounds. As indicated in Structures IIB-D, such compounds can be monofunctional or bifunctional with regard to the α, 62 unsaturated carbonyl group. A commercially available example of a bifunctional disulfide reagent is BAC. An example of a monofunctional disulfide reagent is AEMA (Schnaar, R. L. et al., 1985, Analytical Biochemistry, 151:268-281). Additional monofunctional acrylamide disulfide derivatives can be generated by reacting BAC with the reducting agents β-mercaptoethanol and thioacetic acid, as shown if FIGS. 8 and 9.
-
- In Structural Formula V, R 11 is defined as in Structural Formula IV. “}” represents the point of attachment of the affinity ligand. Methods for derivatizing nucleic acid affinity ligands with an acrylamide group can be found in Boles, et al., U.S. Pat. No. 5,932,711 and Hoffman and Dong, U.S. Pat. No. 5,034,428, the entire teachings of which are incorporated herein by reference.
- A peptide or protein can be derivatized with an acrylamide group by reacting an amine group with an acrylic acid in the presence of a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide. The amine group of the peptide or protein can react with the acrylic acid to form an acrylamide group represented by Structural Formula V. Methods for coupling peptide or protein amine groups with carboxylic acid group, such as the carboxylic acid group of an acrylic acid, can be found in Stewart and Young, Solid Phase Peptide Synthesis, 2nd Edition, Pierce Chemical Company, Rockford, Ill., the entire teachings of which are hereby incorporated by reference.
- Carbohydrates, antigens or drug molecules which have an amine group can also be coupled with acrylic acid to form an acrylamide group using a coupling agent such as dicyclohexylcarbodiimide or diisopropylcarbodiimide. Alternatively, the carboxylic acid group of acrylic acid can be converted into an active ester, such as a p-nitrophenol acrylate, a o,p-dinitrophenol acrylate, or N-hydroxysuccinamide acrylate, and then allowed to react with an amine group of a carbohydrate, antigen or drug molecule.
- A thiol group is a group of the formula —SH. The term “latent thiol group” is intended to include thiol groups which have been protected with a thiol protecting group and disulfide groups of a polymer matrix. The term “thiol protecting group” is intended to include groups which can react with a thiol group causing the thiol group to be unreactive and which can be removed to regenerate the thiol group. Thiol protecting groups are known to those skilled in the art. For examples of thiol protecting groups see Greene, et al., Protective Groups in Organic Synthesis (1991), John Wiley & Sons, Inc., pages 277-308, the teachings of which are incorporated herein by reference in their entirety. In one embodiment, thiol protecting groups can include the following groups:
- The term “Acrydite™ phosphoramidite” as used herein refers to the proprietary acrylamide phosphoranidite sold by Mosaic Technologies, Waltham, Mass. This product allows addition of an acrylamide group directly to a DNA or an RNA oligonucleotide using standard beta-cyanoethylphosphoramidite methods.
- The acronym “AEMA” is intended to encompass the compound known as 4-[[1-Oxo-3-[[2-[(1-oxo-2-propenyl)-amino]ethyl]dithio]propyl]amino]butanoic acid which was obtained from Ronald L. Schnaar, Department of Pharmacology and Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, Md. (Schnarr, R. L. et al., 1985 Analytical Biochemistry 151:268-281).
- The acronym “APS” is intended to encompass an ammonium persulfate such as that available from BioRad Laboratories, Inc., Hercules, Calif.
- The term “acrylate slide” is intended to encompass a slide, e.g, a lass microscope slide, coated with an organosilane compound that includes an acrylamide or acrylic ester functionality. Such slides can be generated by treatment with (3′-acryloxypropyl)trimethoxysilane or other similar compounds available commercially, for example, from Gelest, Tullytown, Pa. Such slides can also be commercially obtained for example, from CEL Associates, Inc., Houston, Tex., (see Cat.# ACR-25C).
- The acronym “BAC” is intended to encompass the compound known as N,N′-bis(acryloyl)cystamine available, for example, from Fluka; Buchs, Switzerland.
- The acronym “DMA” is intended to encompass the compound known as dimethylacrylamide.
- The acronym “DMSO” is intended to encompass the compound known as dimethyl sulfoxide.
- The acronym “DTNB” is intended to encompass the compound known as 5,5′-dithio-bis-(2-nitrobenzoic) acid.
- The acronym “HEMA” is intended to encompass the compound known as 2-hydroxymethacrylate.
- The acronym “ME” is intended to encompass compounds known as mercaptoethanol.
- The acronym “P400 mm” is intended to encompass compounds known as pol(yethylene glycol) 400 monomethyl ether monomethacrylate.
- The acronym “SATP is intended to encompass the compound known as N-succinimidyl S-acetylthiopropionate available, for example, from Pierce; Rockford, Ill.
- The acronym “SBB” is intended to encompass sodium borate buffers.
- The acronym “SDS” is intended to encompass the compound known as sodium dodecyl sulfate.
- The acronym “SSPE” is intended to encompass standard saline phosphate EDTA buffers.
- The acronym “TAA” is intended to encompass thioacetic acids.
- The acronym “TCEP” is intended to encompass the compound known as tris(2-carboxyethyl) phosphine hydrochloride.
- The term “TE buffer” is intended to encompass a 10 mM Tris-HCl pH 8.3; 1 mM EDTA buffer.
- The acronym “TEMED” is intended to encompass compounds known as N,N,N′,N′-tetra-methyl-ethylenediamine available, for example, from BioRad Laboratories, Inc., Hercules,
- The term “GMS spotter” is intended to include a “GMS 417 Arrayer” (Affymetrix; Santa Clara, Calif.).
- In a preferred embodiment, the thiol protecting group is a disulfide group. Disulfide protecting groups can be removed by treating with a disulfide reducing agent which reduces the disulfide bond to form two thiol groups. Disulfide reducing agents include compounds such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP), β-mercaptoethanol and dithiothreitol.
- A solid support having immobilized thiol groups is contacted with an affinity ligand of the invention, which has been derivatized with an acrylamide group. The thiol groups can react with the acrylamide group of the affinity ligand to form a covalent bond via a Michael condensation reaction to form a solid support having immobilized affinity ligands. Therefore, although the term “immobilized” when used in reference to other methods can encompass various means of attachment to a solid support including both ionic and covalent types of bonding, when used in reference to the present invention “immobilized” refers to attachment with a covalent bond.
- The solid supports of the invention can be formed from a variety of materials including paper, glass, silica, metals, ceramics, plastic and polymers. Polymers can be cross-linked to form gels, e.g., electrophoretic gels, e.g., acrylamide gels. The solid supports can be of any shape or dimension. Porous filters, woven materials and meshes, planar sheets, microparticles, fibers, rods, optical fibers, dipsticks, beads, tubes, multiwell plates, cups and capillaries can all be used as solid supports.
- In a preferred embodiment, the solid support of the invention is formed of glass, silica, metal, ceramic or a polymer such as polystyrene, crosslinked polystyrene, polyethylene, polypropylene, polyrmethacrylate, dextran and agarose and a polymer layer is applied to a surface of the solid support. In particularly preferred embodiments, the solid support is formed of glass and a polymer layer is applied to a surface of the solid support. In a particularly preferred embodiment, the solid support is planar in form and contains a polymer layer applied to a surface.
- A preferred embodiment when the solid support is a chromotography bead, e.g., a polyacrylamide bead, is the use of BAC to form the thiol groups.
- In one embodiment, an aliphatic group having a substituted or unsubstituted alkenyl group or a α,β-unsaturated carbonyl group is attached to a surface by contacting the surface with an aliphatic group which has been derivatized with a group that can bind to the surface, thereby forming an unsaturated aliphatic surface. Therefore, selection of a functional group with which the aliphatic group is to be derivatized is dependent on the type of material to which the aliphatic group is to be attached. When the surface to which the aliphatic group is to be attached is doped or undoped silica, alumina, quartz or glass, the aliphatic group is preferably derivatized with a silane group or carboxylic acid. In on embodiment, when the aliphatic group is derivatized with a silane group, the compound can be represented by Structural Formula I.
- In one embodiment, a glass or silica support is treated with an appropriate organosilane compound to provide a surface layer comprising a plurality of alpha-beta unsaturated groups. Preferred silanes include alkoxysilanes and chlorosilanes having vinyl, allylic, acrylamide, methacrylamide or acrylic ester functionalities. One preferred silane is (3′-acryloxpropyl)trimethoxysilane. This and other preferred silanes are commercially available from, for example, Gelest (Tullytown, Pa.).
- When the aliphatic group is to be attached to a surface which is gold, silver, copper, cadmium, zinc, palladium, platinum, mercury lead, iron, chromium, manganese, tungsten, or any alloys of the above metals, the aliphatic group to be attached is preferably derivatized with a thiol, sulfide or disulfide group. When the surface to which the aliphatic group is to be attached is platinum or palladium, the aliphatic group is preferably derivatized with a nitrile or isonitrile group. Finally, when the surface to which the aliphatic group is to be attached is copper, the aliphatic group is preferably derivatized with a hydroxamic acid group.
- An acrylamide gel having latent thiol groups can be formed on the unsaturated aliphatic surface of the solid support by contacting the unsaturated aliphatic surface with a polymerization solution containing a free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide. Conditions for free radical polymerization of disulfide bisacrylamide monomers are similar to those used for polymerization of acrylamide monomers (for example, see Perbal, A Practical Guide to Molecular Cloning, 2nd Edition, (1988), John Wiley & Sons, New York, pages 15-17) and are further described in Example 5 and Example 7. Typically, the polymerization solution contains a disulfide bisacrylamide in about 0.1% to about 20% in an aqueous solution. If an acrylamide and/or a bisalkylene acrylamide is also present, the concentration of the disulfide bisacrylamide and the acrylamide and/or the bisalkylene acrylamide together is about 0.1% to about 20%. Optionally, an organic solvent, such as DMF, can be used to improve reactivity and/or solubility. The polymerization reaction is initiated by a free radical initiator. A free radical initiator is a substance which decomposes to form a free radical. Typical free radical initiators include ammonium persulfate, peroxides, and azo compounds such as azobisisobytyronitrile. Ammonium persulfate is a preferred free radical initiator. About 0.1% (weight/volume) to about 10% (weight/volume) of the free radical initiator is added to the polymerization solution either before the solution is in contact with the unsaturated aliphatic surface or after the polymerization solution is in contact with the unsaturated aliphatic surface.
- Polymerization of the disulfide bisacrylamide on the surface of the solid support forms a solid support having immobilized disulfide groups which are latent thiol groups. The immobilized latent thiol groups can be converted to immobilized thiol groups by contacting the solid support with a disulfide reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP), β-mercaptoethanol and dithiothreitol.
- Comonomers can be added to the BAC for co-polymerization. Useful comonomers include for example, acrylamide, bis acrylamide; N,N-dimethyl acrylamide, N-octyl acrylamide, poly(ethylene glycol) (n) dimethacrylate, n 200 or 400, (Catalog # 00096 and 02364 (1998-2000 “Polymers and Monomers” Catalog, Polysciences, Inc, Warrington Pa.)). A preferred comonomer is pol(yethylene glycol) 400 monomethyl ether monomethacrylate (P400 mm, Catalog # 16665 (1998-2000 “Polymers and Monomers” Catalog, Polysciences, Inc, Warrington Pa.)).
- Other comonomers that could be, used are well known to those practiced in the art of polymer science and coatings; (see, e.g, 1998-2000 “Polymers and Monomers” Catalog, Polysciences, Inc, Warrington Pa.) In addition, it is well known that mixtures of three or more comonomers can be mixed to achieve polymers with desired properties. Comonomers can be added in organic solvents. Optionally, an organic solvent, such as DMF can be used improve reactivity and/or solubility.
- In an alternate embodiment, a solution of acrylamide and non-symmetrical disulfide acrylamides are prepared together with a crosslinking compound such as bis-acrylamide. The mixture is polymerized using ammonium persulfate with TEMED, ultraviolet (UV) light, heat, ionizing radiation or or an equivalent known to those of skill in the art. The disulfide bonds are reduced, for example, using TCEP or a thiol exchange reaction with DTT. Thin polymer layers can be produced by dipping slides in a polymerizing solution. Thicker gels can be formed between glass plates.
- In another embodiment, the solid support is a polymer which has reactive functional groups. Reactive functional groups include amines, amides, hydroxyl, carboxylic acid, and halogens. A preferred polymeric solid support is a polystyrene which has reactive functional soups. Preferred reactive functional groups are amine and hydroxyl groups. The solid support is contacted with a compound which has a functional group which can react with the reactive functional group of the polymer to form a double bond and a substituted or unsubstituted alkenyl or at least one α,β-unsaturated carbonyl to form a solid support having unsaturated aliphatic groups. When the reactive functional group is a halogen, it can react, for example, with an amine or an alkoxide to form a covalent bond. When the reactive functional group is a carboxylic acid, it can react, for example, with an amine or a hydroxide in the presence of dicyclohexylcarbodiimide. When the reactive functional group is an amine or a hydroxyl group, it can react, for example, with an ester, a carboxylic acid or a halogen to form a covalent bond. In a preferred embodiment when the solid support has an amine or a hydroxyl reactive group, it is contacted with a compound is represented by Structural Formula VI:
- In Structural Formula VI, Y and L are as defined in Structural Formula III, and R 10 is a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl. The immobilized unsaturated aliphatic groups are then contacted with a polymerization solution containing a free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide to form a solid support having immobilized latent thiol groups in an acrylamide gel. The latent thiol groups can be activated by contacting the gel with a disulfide reducing agent.
- In another embodiment, the polymeric solid support which is functionalized with an amine or hydroxyl reactive functional groups is reacted with a compound represented by Structural Formula III to form a solid support having immobilized latent thiol groups. In this embodiment, the solid support is preferably, cellulose, celite, poly(acrylic acid), polystyrene, cross-linked polystyrene, an agarose or cross-linked agarose, such as Sepharose or Superose, a cross-linked dextran, such as Sephadex or Sephacryl, or a composite of cross-linked agarose and dextran, such as Superdex. The latent thiol groups are activated by removing the thiol protecting groups. Methods for removing thiol protecting groups can be found in Greene, et al., Protective Groups in Organic Synthesis (1991), John Wiley & Sons, Inc., pages 277-308, the teachings of which are incorporated herein by reference in their entirety.
- In another embodiment, the solid support is silica, alumina, quartz or glass, and the solid support is derivatized with a latent thiol group by contacting the solid support with a compound which has a silane group or a carboxylic acid group and a latent thiol group. In a preferred embodiment, the compound can be represented by Structural Formula VII:
-
- wherein R 11, R12 and R13 are each, independently, a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic group or a substituted or aralkyl group, provided that at least one of R11, R12 or R13 is a halogen. “{” represents the attachment of the silane group to the linking group represented by “L”.
- In another embodiment, the solid support is platinum or palladium, and the solid support is derivatized with a latent thiol group by contacting the solid support with a compound that has a nitrile or an isonitrile group and a latent thiol group. In a preferred embodiment, the compound can be represented by Structural Formula VIII:
- In Structural Formula VIII, R 4 and L are defined as above, and Z1 is a nitrile or an isontrile group.
- In another embodiment, the solid support is copper and the solid support is derivatized with a latent thiol group by contacting the solid support with a compound that has a hydroxamic acid group and a latent thiol group.
- The nucleic acids can be immobilized on the surface of the support in any pattern or arrangement, e.g., blocks, lines, grids or whorls. Nucleic acids with identical nucleotide sequences can be immobilized on the solid support, nucleic acids with non-identical or different nucleotide sequences can be immobilized on the solid support, and combinations of nucleic acids which contain some portion with identical nucleotide sequences and some portions which contain non-identical sequences can be immobilized on the surface of the solid support.
- In particular embodiments, a plurality of nucleic acids, portions of which contain identical nucelotide sequences and portions of which contain non-identical nucleotide sequences, are attached to the solid support in a manner such that nucleic acids with non-identical nucleotide sequences are found on spatially distinct regions of the surface. The phrase “spatially distinct region” is intended to include a region on the surface of a solid support around which an imaginary perimeter can be drawn which does not overlap with the perimeter of any other region.
- The term “array” is intended to include a solid support containing nucleic acids immobilized on at least one spatially distinct region of its surface. An array can contain any number of nucleic acids immobilized within any number of spacially distinct regions. The spacing and orientation of the nucleic acids can be regular, e.g., in a rectangular or hexagonal grid, or the pattern can be irregular or random. In a particular embodiment, nucleic acids containing non-identical nucleotide sequences are arranged in a regular pattern on the surface of a solid support. Such an embodiment is particularly useful, for example, in determining whether a particular set of components are present in a sample. Nucleic acids capable of detecting the presence of each component of the set can be placed in a spacially distinct region, so that in a single analysis, a determination can be made as to whether one or more of the components of the set are contained within the sample. The term “microarray” is intended to include an array in which the spacially distinct regions containing nucleic acids are relatively small.
- An affinity ligand having a thiol reactive group may be contacted with a solid support having free diols either by immersing the solid support in a solution of ligand, or by contacting a drop of ligand to the support. In the latter case, the ligand may be deposited by mechanical contact, as with a metal pin, or the ligand may be sprayed, as with a piezoelectric dispenser. When the ligand is deposited onto the surface with a pin or piezoelectric dispenser, the volume of solution containing the ligand will vary, depending on the conditions used. For example, with the Affymetrix Model 417 pin-loop spotter, the volume deposited depends on the diameter of the loop (see S. Rose, “Applications of a Novel Microarraying System in Genomics Research and Drug Discovery, Journal of Association for Laboratory Automation, 3:(3) 1998) and is in the range of nanoliters (nL) to picoliters (pL).
- The term “sample” or “test sample” are intended to include component mixtures which can contain the target molecule. The test sample can be used directly as obtained from the source or following pretreatment. The test sample can be derived from any biological source, such as a physiological fluid, including, blood, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, peritoneal fluid, amniotic fluid and the like, and fermentation broths, cell cultures, and chemical reaction mixtures and the like. The test sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, and the like. Methods of treatment can involve filtration, distillation, extraction, concentration, inactivation of interfering components, and the addition of reagents. In addition, a solid material such as cells which can contain the target molecule can be used as the test sample. In some instances, it may be beneficial to modify a solid test sample to form a liquid medium or to release a target molecule.
- The solid supports formed by the methods of the invention can be utilized in a variety of assays. Typically, such assays include a hybridization reaction between the immobilized nucleic acid and a target molecule introduced to the solid support, e.g., contained in a test sample. It is clear to one of skill in the art that such methods can be carried out under a range of hybridization conditions utilizing wash conditions with low to high stringencies. Conditions can be selected based on the amount of similarity or differences between the nucleic acids.
- “Stringency conditions” for hybridization is a term of art which refers to the conditions of temperature and buffer concentration (ionic strength) which permit hybridization of a particular nucleic acid to a second nucleic acid in which the first nucleic acid may be perfectly complementary to the second, or the first and second may share some degree of complementarity which is less than perfect. For example, certain high stringency conditions can be used which distinguish perfectly complementary nucleic acids from those of less complementarity. “High stringency conditions” and “moderate stringency conditions” for nucleic acid hybridizations are explained on pages 2.10.1-2.10.16 (see particularly 2.10.8-11) and pages 6.3.1-6 in Current Protocols in Molecular Biology (Ausubel, F. M. et al., eds., Vol. 1, containing supplements up through Supplement 29, 1995), the teachings of which are hereby incorporated by reference. The exact conditions which determine the stringency of hybridization depend not only on ionic strength, temperature and the concentration of denaturants such as formamide or urea, but also on factors such as the length of the nucleic acid sequence, base composition, percent mismatch between hybridizing sequences and the frequency of occurrence of subsets of that sequence within other non-identical sequences. Thus, high or moderate stringency conditions can be determined empirically.
- By varying hybridization conditions from a level of stringency at which no hybridization occurs to a level at which hybridization is first observed, conditions which will allow a given sequence to hybridize (e.g., selectively) with the most similar sequences in the sample can be determined. Binding conditions for triplexes and tetraplexes can be estimated in a similar manner. A general description of stringency for hybridization and wash conditions is provided by Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley-Interscience 1987, & Supp. 49, 2000, the teachings of which are incorporated herein by reference. Factors such as probe length, base composition, percent mismatch between the hybridizing sequences, temperature and ionic strength influence the stability of nucleic acid hybrids. Thus, stringency conditions sufficient to allow hybridization of nucleic acids, can vary significantly. Such conditions can readily be determined by one of ordinary skill in the art.
- Such hybridization reactions take place between nucleotide sequences which are substantially complementary. The phrase “substantially complementary” is intended to include nucleic acid sequences which are sufficiently complementary to hybridize with each other under specified conditions. Typically, complementary nucleic acids contain at least one complementary subsequence. The term “subsequence” is intended to include any contiguous segment of a larger sequence. Thus, a complementary subsequence includes at least one contiguous segment complementary to the nucleotide sequence of another nucleic acid.
- Target molecules separated or detected in the assays of the invention can be amplified. The term “amplified” is intended to include primer dependent nucleic acid synthesis catalyzed by a nucleic acid polymerase. For example, the polymerase chain reaction or hereinafter “PCR” can be utilized to amplify a target molecule. The method can be used in an assay for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
- The solid supports formed by the methods of the invention can be provided in the form of kits. Such kits can contain various components. In one embodiment, a kit can contain a solid support containing a plurality of latent thiol groups. Such a kit can be provided with instructions teaching the purchaser methods for activating the latent thiol groups and for forming a covalent bond between the activated thiol groups and nucleic acids containing an appropriate acrylamide functional group. Such nucleic acids can be synthesized by the purchaser or, alternatively, they can be purchased separately from the kit of the invention. Kits containing components in addition to a solid support containing immobilized thiol groups are also within the scope of the invention. Such kits can contain components for activating the thiol groups, e.g. reducing agents and/or a wash buffer. Such kits can also contain nucleic acids with acrylamide functional groups. The nucleic acids can be identical, non-identical or a combination can be provided. Typically, components of the kits are contained in separate containers.
- In an alternate embodiment, a kit can contain a solid support containing a plurality of latent thiol groups and nucleic acids containing an appropriate acrylamide functional group. Kits containing components in addition to a solid support containing immobilized thiol groups and nucleic acids containing an appropriate acrylamide functional group are also within the scope of the invention. Such kits can contain components for activating the thiol groups, e.g., reducing agents and/or a wash buffer. Typically, components of the kits are contained in separate containers.
- The features and other details of the invention will now be more particularly described and pointed out in the examples. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention.
- FIG. 1 depicts schematically one method for covalently bonding acrylamide functional nucleic acids to a polystyrene support. In
Step 1, the formation of latent thiol groups on amino-functional polystyrene is illustrated. Approximately 10 μL of amino-functional polystyrene microspheres (10% suspension) were dispersed in 80 μl of phosphate buffer (50 mM, pH=7.5). The amino-functional polystyrene microspheres had a diameter of approximately 1 μm and an amino group density of approximately 75 μeq/g (Bang's Laboratories Inc., Fisher, Ind.). To the polystyrene microsphere suspension, 368 μg of N-succinimidyl S-acetylthioipropionate (hereinafter “SATP”), (Pierce, Rockford, Ill.) in 10 μl of dimethyl sulfoxide (hereinafter “DMSO”) was slowly added. This mixture was gently shaken for approximately two (2) hours at ambient temperature. The microspheres were then washed three (3) times, each time with 100 μl of phosphate buffer (50 mM, pH=7.5), by adding the phosphate buffer and mixing, centrifuging, and decanting the supernatant, to provide latent thiol microspheres after the final decanting step. - (The latent thiol derivatized microspheres, also referred to as thiolated microspheres, can optionally be dried and stored at this point for future use. If dried, the thiolated microspheres can be rehydrated in phosphate buffer prior to continuing with
Step 2.) The following steps were performed to provide oligonucleotide functional polystyrene microspheres. - As illustrated, in
Step 2, the activation of latent thiol (deacetylation) was described. Deacetylation buffer was prepared containing 50 mM phosphate buffer, 25 μM EDTA and 0.5 M of hydroxylamine HCl. It had a final pH of 7.5. Next, 100 μl of the deacetylation buffer was added to the latent thiol microspheres in the centrifuge tube fromStep 1. The centrifuge tube was gently shaken for two (2) hours at ambient temperature. After centrifugation, the supernatant and microspheres were separated by decantation providing activated microspheres in the tube. -
Step 3 describes oligonucleotide attachment. To the centrifuge tube fromstep 2, 100 μl of 1X TE buffer were added, along with 1.0 μl of acrylamide-modified oligonuleotide primer pair solution having a concentration of 100 μM for each oligonucleotide (Operon Technologies, Alameda, Calif.). The microsphere suspension was then gently shaken for one (1) hour at ambient temperature. Oligonucleotides covalently bound through a thioether linkage to activated microspheres (oliogonucleotide bound microspheres) were obtained. - In
Step 4, an optional step of blocking the excess reactive thiol groups is described. Excess thiol groups on the oligonucleotide bound microspheres can be blocked, if desired. To block the excess thiol groups on the microspheres, 277 μg of iodoacetamide (Aldrich Chemical Co., Milwaukee, Wis.) dissolved in 10 μl of1X 10 mM Tris-HCL pH 8.3; 1 mM EDTA buffer (hereinafter “TE buffer”) was added to the oligonucleotide bound microspheres ofStep 3. The centrifuge tube and its contents were then shaken for one (1) hour at ambient temperature. The TE buffer was decanted off the microspheres. Then, the microspheres were washed three (3) times with 100 μl each of TE buffer to provide capped, oligonucleotide bound microspheres. After decanting the last wash, the capped oligonucleotide bound microspheres in the tube were ready for use in a PCR reaction, for example, as illustrated in U.S. Pat. No. 4,683,202, the disclosure of which is incorporated herein by reference. (Alternatively, the capped oligonucleotide microspheres can be dried and stored at this point for future use. If dried, the capped oligonucleotide microspheres can be rehydrated in phosphate buffer prior to use.) - A glass slide having a plurality of amine groups attached in a substantially uniform spatial pattern to a flat surface thereof (Part #S 4651, aminoalkyl silane coated slides, Sigma Chemical Co., St. Louis, Mo., 1999 catalog) was submerged for two (2) hours at ambient temperature in a solution of 15 mM SATP in 50 mM phosphate buffer pH 7.5, 10% DMSO. The glass slide was then washed three (3) times with 50 mM, pH 7.5 phosphate buffer by submerging the glass slide in phosphate buffer. A glass slide having a plurality of latent thiolated groups was formed.
- The glass slide was submerged in a solution of deacetylation buffer which contains 50 mM of phosphate buffer pH 7.5, 25 μM of EDTA and 0.5 M of hydroxylamine-HCl, for two (2) hours at ambient temperature to provide a glass slide having a plurality of activated thiol groups.
- A plurality of acrylamide-modified oligonucleotides were attached to the activated thiol groups. A lass slide was uniformly modified with acrylamide-modified nucleic acids by submerging the activated glass slide in a 100 μM solution of acrylamide-modified oligonucleotide in 1X TE buffer (Acrydite™ acrylamide-modified oligonucleotide obtained from Operon Technologies, Alameda, Calif.) for one (1) hour at ambient temperature.
- A plurality of acrylamide-modified oligonucleotides, each having a different sequence, were deposited onto the slide in spatially distinct regions. Deposition of the oligonucleotides onto the activated array was performed manually, although it could also have been performed automatically (e.g., using a pipetting robot). Using a micropipette dipped into an acrylamide-modified oligonucleotide solution, an aliquot of the solution was transferred to a predetermined region on a lass slide having activated thiol groups. A second acrylamide-modified olionucleotide was then deposited onto a second region that is spatially distinct from the first region, using the same procedure with a fresh micropipette.
- Alternatively, a capillary dispenser, for example, one as illustrated in U.S. Pat. No. 5,807,522, the teachings of which are incorporated herein by reference, can be used. Other spotting methods known to those skilled in the art, which permit the regions of the array to be arranged so that the oligonucleotide sequences are appropriately spaced, can also be used.
- In an alternative embodiment, random arrays are formed using an ink-jet spray apparatus such as, for example, the apparatus illustrated in U.S. Pat. No. 5,599,695, the teachings of which are incorporated by reference in their entirety. In yet another embodiment, regions of an array can be defined utilizing a mask, such as those utilized in photolithography.
- After deposition of all oligonucleotides on the array, activated thiol groups that have not been covalently linked to an acrylamide-modified oligonucleotides are blocked. For example, the method of
Step 4 in Example 1 above can be used to inactivate remaining thiol groups. Other chemical treatments known to those of skill in the art can also be utilized. - A polystyrene flat support having a plurality of amine groups attached in a substantially uniform spatial pattern to a flat surface thereof is submerged for two (2) hours at ambient temperature in a solution of 15 mM SATP in dimethyl sulfoxide-phosphate buffer. Then, the polystyrene flat support is washed three (3) times with 50 mM, pH=7.5 phosphate buffer, submerging the polystyrene flat support in phosphate buffer to provide a polystyrene flat support having a plurality of latent thiolated sites.
- Deacetylation buffer which contains 25 μM EDTA, 0.5 M hydroxylamine-HCl in 50 mM phosphate buffer is prepared with a final pH of 7.5. It is mixed with 100 mM acrylamide-modified oligonucleotides (Operon Technologies, Alameda, Calif.) in 1X TE buffer. The solution is selectively spotted onto the latent thiol sites in predefined regions. Since only selected areas on the support are provided with activated thiol groups through contact with the deacetylation buffer, only those regions are available for binding acrylamide-modified oligonucleotides. Thus, latent regions remain and can be used to separate the regions to which oligonucleode has been covalently bound.
- In yet another alternative embodiment, a glass slide can be provided with amine groups in a predefined pattern. The amine groups can then be converted to latent thiol groups and the support treated as described in Example 2.
- This example demonstrates attachment of acrylamide-modified oligonucleotide probes to a crosslinked polyacrylamide gel support containing the disulfide bisacrylamide crosslinker N,N′-bis(acryloyl)cystamine, (hereinafter “BAC”, Fluka, Buchs, Switzerland). Acrylamide groups on the oligonucleotide probes were added during synthesis using commercially available acrylamide phosphoramidites (Acrydite™ phosphoramidites I and III, Mosaic Technologies, Waltham, Mass.). Solid phase hybridization performance of 5′-methacrylamide-modified oligonucleotide probes, indicated by “Ac1” (generated with Acrydite™ I) 220 were compared with 5′-acrylamide-modified oliganucleotide probes, indicated by “Ac3” (generated with Acrydite™ III) 210. In all cases, (FIGS. 2A, 2B), oligonucleotide probes were spotted onto thiol containing gel-coated slides and allowed to react. The slides were washed to remove unbound probe, and then hybridized to a fluorescently labeled oligonucleotide target to reveal the hybridization performance of the immobilized probes. Control experiments (not shown) demonstrated that when tris(2-carboxyethyl) phosphine hydrochloride (hereinafter “TCEP”) treatment was omitted, images similar to FIG. 2B were produced, thus, demonstrating that activated, reduced thiols (but not latent thiols) were required for probe binding. FIG. 2B shows that 5′-acrylamide probe binding was prevented by pretreating the TCEP-treated slide with excess monomer acrylamide, suggesting that the acrylamide function of the probes are important for binding. FIG. 2A also demonstrates that 5′
230 and 5′amino hydroxyl 240 modified oligonucleotide probes show low binding to gels containing activated thiol groups. - Step 1: Preparation of Acrylate Slide Bound to Acrylamide Gel Layer
- Aqueous acrylamide solution was prepared using 6% acrylamide (29:1 ratio of acrylamide monomer to bisacrylamide (BioRad laboratories, Inc.; Hercules, Calif.) and 0.5% (wt/v) N,N′-bis(acryloyl)cystamine (Fluka, Buchs, Switzerland)) in 100 mM sodium borate buffer pH 9 hereinafter “SBB”). The aqueous solution was cooled on ice. A 100 μl aliquot was mixed with 1 μl fresh 10% ammonium persulfate (hereinafter “APS”, BioRad Laboratories, Inc., Hercules, Calif.) and 1 μl N,N,N′,N′-tetramethyl-ethylenediamine (hereinafter “TEMED”; BioRad, Hercules, Calif.) diluted 10:1 with water to provide an acrylamide gel solution. Next, 30 μl of the acrylamide gel solution were pipetted onto an acrylate slide (Cat# ACR-25C, CEL Associates, Inc., Houston, Tex.) that is at room temperature. The acrylamide gel solution was overlaid with a glass coverslip (24×50 mm) taking care not to create any air bubbles or gaps. The acrylamide gel solution was allowed to polymerize on the acrylate slide for at least 45 minutes at room temperature. The coverslip was removed leaving an acrylamide gel layer having latent thiol groups bound to the acrylate slide.
- (At this point, the slides can be also be dried and stored for later use after rehydration.)
- Step 2: Activation of the Latent Thio Groups
- The acrylate slides each having a thio-derivatized acrylamide gel layer were placed in 20 mM TCEP (Fluka; Buchs, Switzerland) in 100 mM SBB pH 9 and were incubated for 15 minutes.
- The slides were washed two (2) times in TE buffer, then rinsed with water and allowed to air dry.
- Step 3: Oligonucleotide Attachment to Acrylamide Gel
- The slides were spotted within 30 minutes of TCEP treatment with oligonucleotides modified as described. Spotting solutions were prepared with 100
mM SBB pH 9 and 20 μM oligonucleotide (Operon, Alameda, Calif.) containing 5′ Acrydite III modification, 5′ Acrydite I modification, 5′ NH2 modification, or without a 5′ modification. Individual spots of 0.5 μl of each solution (10 pmoles) were placed onto each slide in triplicate. The slides were placed in a nitrogen box and incubated for one (1) hour at room temperature. Then, the slides were washed two (2) times with TE+0.2M sodium chloride (hereinafter “NaCl”). The slides were washed two (2) times in TE pH8 and allowed to dry. - Step 4: Oligonucleotide Detection By Hybridization
- An aliquot of 60 μl hybridization mix (10 μM complementary fluorescent oligonucleotide (OPERON, Alameda, Calif.) in 5X SSPE+0.2% SDS was placed on the slide and the slide was overlaid with a coverslip. The slides were allowed to hybridize for one (1) hour at room temperature in a humid hybridization chamber (Corning, Corning, N.Y.). Amer one (1) hour, the slides were washed two (2) times with 1X SSPE+0.1%, SDS. Then, each slide was washed one (1) time with TE at pH 8 and was allowed to air dry.
- The slide is imaged dry in a fluorescent imager (Molecular Dynamics, Fluorimager 595, Sunnyvale, Calif.).
- Step 1: Preparation of Gel-Coated Slide Supports
- A polymerization solution was prepared with 6% acrylamide (29:1), and 0.5% BAC (wt/v), in 100 mM SBB pH9. (BAC required heating and vortexing to go into solution). 1 μl fresh 10% APS (made same day) and 1 μl of 10:1 dilution of H 2O:TEMED were added to 100 μl of the solution and mixed thoroughly. 10 μl of solution were pipetted onto an Acrylate Slide (CEL Associates, Inc., ACR-25C) and overlaid with a lass overslip (18×18 mm), taking care not to create any air bubbles or gaps in the solution. The acrylamide layer was allowed to polymerize at least 20 minutes at room temperature. After the slides were rinsed in TE and allowed to air dry, they were ready for spotting of oligo.
- Step 2: Activation of the Latent Thiol Group
- Spotting solutions were prepared from 20 μM of Acrydite™ oligo and 100 mM TCEP, all in 100 mM SBB at pH 9.
- 35 μl of various solutions were prepared and placed in a microtiter plate.
TABLE 1 Well Well Well Pin Slide Slide # oligo Col Row Probe Replicate # Abs Abs A1 Tryp 370 1 1 0 1 5.5 40 A3 Tryp 355 3 1 0 1 5.8 40 A5 Tryp 575 5 1 0 1 6.1 40 A7 no oligo 7 1 0 1 6.4 40 A9 blank 9 1 0 1 6.7 40 A11 blank 11 1 0 1 7 40 A2 Bglobar1269 2 1 0 2 14.5 40 A4 Bglobar1287 4 1 0 2 14.8 40 A6 Bglobar490 6 1 0 2 15.1 40 A8 ANF401 8 1 0 2 15.4 40 A10 no oligo 10 1 0 2 15.7 40 A12 blank 12 1 0 2 16 40 - Step 3: Oligonucleotide Attachment to Acrylamide Gel
- The slides were arrayed on a GMS spotter as follows:
- The slides were incubated on a lab bench at room temperature for one (1) hour. After one (1) hour, the slides were soaked for 30 minutes in 20% dimethylacrylamide (hereinafter “DMA”) or 20% 2-hydroxyethylmethacrylate (hereinafter “HEMA”) in 100 mM SBB at pH 9. The slides were washed two (2) times with TE+0.2M NaCl. Then, the slides were washed once in TE and allowed to dry.
- Step 4: Oligonucleotide Detection by Hybridization
- Adhesive hybridization chambers were attached to the slides and 90 μl of the hybridization mixture were added to slides: cDNA prepared from 50 ng input globin RNA in 4X SSPE+0.2% Tween. The slides were hybridized overnight at 55° C. in a humid hybridization chamber. After incubation, the slides were washed two (2) times with 1XSSPE+0.1% Tween. Then, the slides were washed one (1) time with TE and allowed to air dry. The slides were imaged dry.
- When quantified, blocking with HEMA is comparable to slide with DMA. Background with HEMA block is slightly higher, but the difference is not significant. The results, both when blocked with DMA and blocked with HEMA, are shown in FIGS. 3A-3B.
- The following were mixed in a 15 ml tube:
Final conc: 0.5 ml dimethylformamide (DMF) 5.0% 50 mg N,N′-bis(acryloyl)cystamine (BAC) 0.5% (19.2 mM) 1.5 ml 40% stock acrylamide/bis solution6.0% (844 mM) 2.0 ml 500 mM Tris-Glycine buffer pH 9.0 100 mM 6.0 ml water 10 ml total volume - 1 ml of the above solution was placed on ice and added to:
1 μl 1% SDS0.001% 10 μl 10% aqueous APS0.1% 10 μl 10% aqueous TEMED0.1% - 10 μof the above solution was pippetted onto a microscope that was coated with an acrylic silane (CEL Associates, Inc., Houston, Tex.) and overlaid with a lass coverslip (18×18 mm) taking care not to create any air bubbles or gaps in the solution. The solution was allowed to polymerize for 30 minutes at room temperature. The coverslip was removed using a razor blade. The slides were washed in TE buffer and allowed to dry at room temperature.
- 123 mg of AEMA were dissolved in 0.5 ml dimethyl formamide (hereinafter “DMF”) and 1.5 ml water. After the AEMA was dissolved the following was added:
Final conc: 1.5 ml 40% stock acrylamide/bis solution6.0% (844 mM) 2.0 ml 500 mM Tris-Glycine buffer pH 9.0 100 mM 5.0 ml water 10 ml total - 1 ml of the above solution was taken, placed on ice and the following was added:
1 μl 1% SDS0.001% 10 μl 10% aqueous APS0.1% 10 μl 10% aqueous TEMED0.1% - 10 μl of the above solution was pippetted onto a microscope that was coated with an acrylic silane (CEL Associates, Inc. Houston, Tex.) and overlaid with a glass coverslip (18×18 mm) taking care not to create any air bubbles or gaps in the solution. The solution was allowed to polymerize for 30 minutes at room temperature. The coverslip was taken off using a razor blade. The slides were washed in TE buffer and allowed to dry at room temperature.
- The following was added to a 15 ml tube:
100 mg BAC 1.0% (0.384 mmole) 0.5 ml DMF 0.5 ml water - After BAC dissolved, the following was added:
27.5 ml β-mercaptoethanol dissolved in 0.5 ml water (0.384 mmole) - The solution was allowed to react for 1-12 hours at room temperature. After incubation the following was added:
Final conc: 1.5 ml 40% stock acrylamide/bis solution6.0% (844 mM) 2.0 ml 500 mM Tris-Glycine buffer pH 9.0 100 mM 5.0 ml water 10 ml total - 1 ml of the above solution was taken, placee on ice and the following was added:
1 μl 1% SDS0.001% 10 μl 10% aqueous APS0.1% 10 μl 10% aqueous TEMED0.1% - 10 μl of the above solution was pippetted onto a microscope that was coated with an acrylic silane (CEL Associates, Inc. Houston, Tex.) and overlaid with a glass coverslip (18×18 mm) taking care not to create any air bubbles or gaps in the solution. The solution was allowed to polymerize for 30 minutes at room temperature. The coverslip was taken off using a razor blade. The slides were washed in TE buffer and allowed to dry at room temperature.
- The following was added to a 15 ml tube:
100 mg BAC 1.0% 0.384 mmole 0.5 ml DMF 0.5 ml water - After the BAC was dissolved, the following was added:
43.8 mg thioacetic acid 0.384 mmole - After the incubation, the following was added:
Final conc: 1.5 ml 40% stock acrylamide/bis solution6.0% (844 mM) 2.0 ml 500 mM Tris-Glycine buffer pH 9.0 100 mM 5.0 ml water 10 ml total - 1 ml of the above solution was taken, placed on ice and the following was added:
1 μl 1% SDS0.001% 10 μl 10% aqueous APS0.1% 10 μl 10% aqueous TEMED0.1% - 10 μl of the above solution was pippetted onto a microscope that was coated with an acrylic silane (CEL Associates, Inc. Houston, Tex.) and overlaid with a glass coverslip (18×18 mm) taking care not to create any air bubbles or gaps in the solution. The solution was allowed to polymerize for 30 min. at room temperature. Take off the overslip using a razor blade. Wash the slides in TE buffer and allow to dry at room temperature.
- Three different types of supports were prepared.
- Standard support containing 0.5% BAC (19.2 mM disulfide bonds yielding 38.4 mM thiol groups after reduction). The preparation is described in Example 7 above.
- AEMA support containing 38.4 mM AEMA and 38.4 mM thiol groups bound to the gel after reduction. The preparation is described in Example 8 above.
- BAC+ME gel pad containing 38.4 mM BAC and 38.4 mM thiol groups bound to the gel after reduction. The preparation is described in Example 9 above.
- After polymerization, two slides of each type were washed and treated with 10 mM TCEP solution in 100 mM sodium carbonate,
pH 10 for 20 min. Another slide prepared with a gel layer containing no BAC was treated the same way. The slides were washed four (4) times in 1X SSPE buffer containing 0.1% SDS. Then the slides were washed two (2) times in 10 mM TE buffer pH 8. - The conversion of disulfide groups into thiol groups was confirmed by spotting 0.5 μl of 1
5,5′-dithio-bis-(2-nitrobenzoic acid) (hereinafter “DTNB”) solution in 100 mM phosphate buffer pH 8 on the gel. The spot turned yellow on AEMA and BAC containing gel layers, but remained colorless on a control slide with just acrylamide gel layer. This indicated that all TCEP was eluted from gel layers.mM - A series of solutions of 50 μl volume was prepared for spotting on slides. The solutions contained different concentrations (3, 10 and 30 mM) of Acrydite™-modified DNA olionucleotide BD 1216 (complementary probe for rabbit globin cDNA target) in either 100 mM Tris-Glycine pH 9 or 100 mM
sodium carbonate pH 10 buffer. Also, solutions containing 10 mM oligo and 10% or 20% glycerol were prepared. (Glycerol containing solutions are less sensitive to humidity of air during spotting and give higher yields of DNA probes binding in low and moderate humidity) In this experiment, all gel solutions were reduced with TCEP before spotting and no TCEP was added into spotting solutions. - The solutions were placed in a microplate well (Microseal 96 V-bottom microplates, MJ Research, Mass.) and the arrays were spotted using a Genetic Microsystems 417 Arrayer (Affymetrix, Santa Clara, Calif.) and incubated overnight at room temperature.
- The residual activated thiols were quenched by soaking the slides in 10% acrylamide solution, 100 mM sodium
carbonate buffer pH 10, for 20 minutes. to improve background between spots, then washed two (2) times in 10 mM TE+200 mM NaCl, followed by two (2) times in 10 min TE and dried. - Hybridization was carried out overnight at 55° C. in plastic chambers with rabbit globin cDNA labeled with Cy3 fluorescent dye. Concentration of cDNA was 50 ng/ml of hybridization buffer (4X SSPE containing 0.02% Tween 20). After hybridization, the slides were washed three (3) times in 1X SSPE buffer and briefly washed two (2) times in 10 mM TE buffer, then dried using nitrogen.
- The arrays were scanned with
ScanArray 4000 scanner (GSI Lumonics, Watertown, Mass.) using green line 543.5 nm of HeNe laser for excitation. The laser power was set at 90% and photomultiplier power (PMT) was set at 60%. The data was analyzed using ImageQuant 5.1 software (Molecular Dynamics, Sunnyvale, Calif.). The background signal from an unspotted position on the microarray was subtracted from the total fluorescence signal of each hybridized probe spot. - The corrected fluorescence intensity data are plotted in FIGS. 6 and 7. FIG. 7 compares the Tris-Glycine buffer with the carbonate buffer. At each concentration of probe oligonucleotide tested, better hybridization signals were obtained when the probes were spotted with the carbonate buffer system. FIG. 7 shows data only for the 10 μM probe spots.
- In addition, slightly better signals were obtained using the monofunctional disulfide acrylamide, AEMA. Similar enhancement of hybridization signals resulted from using a gel layer containing BAC that had been reduced with an equimolar amount of mercaptoethanol prior to gel polymerization. Similar hybridization enhancements were also obtained from gel layers containing BAC that had been reduced with thioacetic acid prior to gel formation, as described in Example 10 (data not shown). While not wishing to be bound by theory, the enhancement may result from the fact that BAC derived thiols in gels cast with unreduced BAC, as in the BAC protocol of Example 7, may be held in close proximity after reduction in the gel, and therefore may reform the disulfide, thereby reducing the number of thiol groups available for probe binding.
- Acrylate slides were co-polymerized in BAC solutions containing concentrations of BAC ranging from 1% to 6%. A 1% BAC coated slide was made by mixing 3 ml of 10% BAC in DMF; 12 ml of DMF; 15 ml of water and 600 μL of 25% APS; 100 μL TEMED. After mixing, this solution was dispensed into a container with four acrylate slides; the solution was allowed to polymerize overnight at room temperature. A white homogenous gel-like material signaled the visible onset of polymerization. The BAC acrylate slides were then removed from the solution and rinsed in deionized water with gentle rubbing to remove the visible white film formed on the BAC acrylate slide.
- After treatment with TCEP to generate active thiols, the slides were spotted with an Acrydite™ oligonucleotide (50mer) designed to hybridize to cDNA transcribed from the mRNA of the rabbit beta-globin gene. The concentrations of 30-mer used for the spots were 30 μM, 10 μM, 5 μM, 1 μM, and 0 μM. Acrydite™ modified oligonucleotide bound to the BAC acrylate slide was hybridized overnight at 55° C. in 4X SSPE; 0.02% Tween20® to Cy3-dUTP labeled cDNA (prepared from rabbit reticulocyte polyA+mRNA (Gibco-BRL; Life Technologies; Rockville, Md.) with an arrayTRACKER™ Standard Labeling cDNA Kit (Cat. #490-100, Displays Systems Biotech, Inc.; Vista, Calif.) in accordance with the instructions provided with the kit using the following modification: After the final precipitation in the display systems protocol, the cDNA preparation was resuspended in 40 μL buffer (4X SSPE; 0.02% Tween20®), and this mixture was run through a G25 spin column (Cat. # 27-5325-01 Amersham Pharmacia, Microspin G-25 column). The hybridized spotted slide was washed three (3) times in 1X SSPE buffer containing 0.02% Tween20®, then in TE, and then dried with a stream of nitrogen. The hybridized oligonucleotide spotted slide was imaged with a
GSI Lumonics ScanArray 4000 Microarray Analysis System (GSI Lumonics, Inc.; Billerica, Mass.). - The results demonstrated that the amount of cDNA bound depends on the amount of BAC used to prepare the slide. Optimal signals are seen with BAC concentrations of 1-3%
TABLE 2 Effect of BAC conc slide % BAC Signal Background 01 1 3,839 71 05 0.5 1,798 52 06 1.5 4,275 67 07 3 7,479 75 08 6 3,315 83 - A procedure similar to that in Example 7 was used to make slides with 2% BAC, with various amounts of P400 mm. To make a slide with a coating of 2% BAC-1% P400 mm, four acrylate slides were immersed in a solution made by mixing: 3.6 ml of 10% BAC in DNEF, 5.4 ml of DMF; 9 ml of water; 180 μL of P400 mm; 240 μL of 25% APS; 40 μL TEMED After standing at room temperature, the appearance of the solution was noted. The BAC acrylate slides were then removed from the solution and rinsed in deionized water. In cases where a film was visible on the slides, gentle rubbing was used to remove the visible white film. The BAC acrylate slides were again washed in water, and then dried with a stream of nitrogen.
- After treatment with TCEP to generate active thiols, the slides were spotted with an Acrydite™ modified oligonucleotide (50mer) designed to hybridize to cDNA transcribed from the mRNA of the rabbit beta-globin gene. The concentrations of 50-mer used for the spots were 30 μM, 10 μM, 5 μM, 1 μM, and 0 μM. Acrydite™ modified oligonucleotide bound to the BAC acrylate slide was hybridized overnight at 55° C. in 4X SSPE; 0.02% Tween20® to Cy3-dUTP labeled cDNA (prepared from rabbit reticulocyte polyA+mRNA (Gibco-BRL; Life Technologies, Rockville, Md.) with an arrayTRACKER™ Standard Labeling cDNA Kit, (Cat. #490-100, Displays Systems Biotech, Inc.; Vista, Calif.) in accordance with the instructions provided with the kit, except that after the final precipitation in the display systems protocol, the cDNA preparation was resuspended in 40 μL of buffer (4X SSPE; 0.02% Tween20®), and this mixture was run through a G25 spin column (Cat. #27-5325-01, Amersham Pharmacia, Microspin G-25 column). The hybridized spotted slide was washed three (3) times in 1X SSPE buffer containing 0.02% Tween20®, then in TE, and then dried with a stream of nitrogen. The hybridized oligonucleotide spotted slide was imaged with a
GSI Lumonics ScanArrayR 4000 Microarray Analysis System (GSI Lumonics, Inc.; Billerica, Mass.). - Addition of P400 mm in the range of 0.5 to 4% (v/v) was seen to change the nature of the precipitate formed during polymerization reaction. Depending on the concentration of P400 mm, the solution formed a clear gel, a cloudy gel, or no visible gel i.e., remained a liquid. When the solution remained a liquid, no film was formed on the slides, and the rubbing step above was not necessary.
- The following Table shows the results obtained for slides prepared with different concentrations of P400 mm in 2% BAC.
TABLE 3 Back- Slide % Signal* ground* Film Appearance # P400 mm Rfu Rfu After Polymerization 01 0.0 796 97 White, soft gel 02 0.5 3,188 26 White, soft gel 03 1.0 4,243 68 Bluish, grey firm gel 04 2.0 2,530 45 Clear, liquid 05 4.0 637 34 Clear, firm gel - The data also showed that the amount of cDNA bound was dependent on both the amount of comonomer, and the concentration of 50-mer oligo used in spotting, as shown in the following table:
TABLE 4 Effect of Conc of spotted oligo slide oligo % BAC % p400 mm signal S-B S/ B 01 30 2 0 796 699 8.2 10 2 0 307 210 3.2 5 2 0 245 148 2.5 1 2 0 150 53 1.5 0 2 0 97 0 1.0 03 30 2 1 4,243 4,175 62 10 2 1 2,200 2,132 32 5 2 1 1,308 1,240 19 1 2 1 406 338 5.9 0 2 1 68 0 1.0 - Signal—sum of the RFUs for each pixel in an area corresponding to the region of the spotted oligo
- S-B signal minu the signal for spot with 0 oligo.
- S/N singal divided by the signal for spot with 0 oligos.
- Addition of comonomer also results in a change in the size of the spot made by the oligonucletide in solution. FIG. 4 shows a plot of fluorescent intensity across a spot for slides prepared with 2% BAC or 2% BAC plus P400 mm at the different concentrations.
- 1% BAC in water coated slides were prepared as follows: 0.5 g of BAC was dissolved in 50 ml of deionized water at 70° C. Acrylate slides were completely submerged in the heated BAC solution. 1.0 ml of 0.05% APS and 1.0 ml of 0.05% TEMED were added The container was sealed and shaken for 1 minute. The polymerization reaction was complete within several minutes. A white precipitate of polyBAC formed. After removal of the macroscopic polyBAC particulate with water, the acrylate slides appeared coated with a homogeneous thin white film. This film was removed by gentle scrubbing under water. The resulting dried BAC acrylate slides appeared clear and transparent with no visible residue.
- A BAC acrylate slide was then spotted with different concentrations ranging from 30 μM to 1 μM of beta-globin-specific 70mer Acrydite™ modified oligonucleotide containing TCEP in the spotting solution. The spots were visualized by hybridization with Cy3 labeled globin cDNA (10 ng/80 ul) in 100 μl of 20× saline sodium phosphate EDTA buffer (SSPE; 3.6 M sodium chloride, 200 mM sodium phosphate, pH 7.4, 20 mM EDTA, pH 7.4) in a hybridization chamber. The visualized spots formed are shown in FIG. 5, a photograph of the BAC acrylate slide after hybridization to a fluorescent complementary oligonucleotide probe.
- When the dried BAC acrylate slide were soaked in 50 mM TCEP for 30 minutes prior to spotting and TCEP was left out of the spotting solution, the results shown in FIG. 5B were obtained. When SDS at 0.01% in carbonate buffer (100 MM, pH 10.0) was used as the spotting buffer with the Acrydite™ modified oliogonucleotide on a dried BAC acrylate slide exposed to TCEP for 30 minutes prior to spotting, the results shown in FIG. 3C were obtained.
- A piece of nylon screen is placed between two silane treated glass plates. An edge of the nylon screen is allowed to extend from between the plates. A measured aliquot of the gel solution from Example 5 is placed on the extension and the solution is wicked onto the nylon screen between the two glass plates. The solution is allowed to gel. Prior to use the slide is activated and provided with Acrydite™ modified oligonucleotides as above.
- Provide a polyacrylamide gel matrix wherein the polyacrylamide matrix has dithiol cross-linkages (no nucleic acid or protein probes) such as, for example, by following Example 5,
Step 1. In addition to the reagents for forming the thiol-derivatized acrylamide gel solution, mix in a desired cell type for culture. For example, E. coli provided with nutrient culture reagents may be grown within the polymerized gel. To release the bacterial cells after replication has occurred, cleave the dithiols to the degree desired, for example by following the procedure described in Example 5,step 2 to release the cells. - Varying the amount of acrylamide cross linker used will allow regulation of the density of the gel.
- Following the procedure described in Example 5,
Step 1 using a bisacrylamide cross-linker with bound Acrydite™ modified oligonucleotides having a desired primer sequence to provide a thiol derivatized acrylamide gel solution additionally having bound oligonucleotides. To this gel solution, add the reagents (to include a second primer in solution where desired; nucleic acids; enzyme) required to allow amplication by polymerase chain reaction cycling and a sample thought to contain the nucleic acid fragment to be amplified. Allow the gel solution to polymerize on a support such as the acrylate slide and expose the slide to PCR cycling conditions. Cleave the latent thiol groups using a procedure such as that described in Example 5,Step 2. Release and remove the amplified nucleic acid. - Acryl-silane coated microscope slides (Gel Associates, Inc., Houston, Tex.) were submerged in 0.1-2% heated BAC/water solution. 100-400 μl or 10% APS and 10% TEMED were added per 50 ml of solution for a rapid polymerization. Chain terminators, e.g., isopropanol, can be added prior to polymerization to induce short chain growth. N,N′ methylenebisacrylamide (hereinafter “BIS”) can be added to the BAC solution at the appropriate concentration prior to polymerization to allow multiple chain growth or polymer branching. Polymerization is complete within 5 minutes or upon the formation of a white particulate (polyBAC). The white particulate can be removed from the slides under water by a gentle hand scrub. Slides were suspended in 5-100 mM TCEP for reduction of disulfides. Thiol formation was immediately evident by development of a putrid odor. The slides were then dried for spotting.
- While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those of skill in the art that various changes in form and details may be made herein without departing from the scope of the invention encompassed by the appended claims.
Claims (71)
1. A method of immobilizing an affinity ligand on a solid support comprising:
providing a solid support comprising an immobilized thiol group;
contacting the thiol group with a nucleic acid comprising an acrylamide functional group; and
forming a covalent bond between the two groups,
thereby immobilizing the ligand on the solid support.
2. The method of claim 1 , wherein the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog.
3. The method of claim 2 , wherein the solid support comprises a plurality of thiol groups
4. The method of claim 3 , wherein a plurality of ligands are immobilized on the solid support.
5. The method of claim 4 , wherein the solid support is formed from a compound selected from the group consisting of class, plastic and metal.
6. The method of claim 5 , wherein the solid support comprises two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids.
7. The method of claim 6 , wherein the solid support further comprises a polymer layer.
8. The method of claim 7 , wherein the solid support comprises a microarray.
9. The method of claim 1 , wherein the thiol groups comprise reduced disulfide groups.
10. A method of immobilizing an affinity ligand on a solid support comprising the steps of:
providing a solid support comprising immobilized latent thiol groups;
activating the latent thiol groups; and
reacting the activated thiol groups with an affinity ligand having at least one acrylamide functional group, thereby immobilizing an affinity ligand on a solid support.
11. The method of claim 10 , wherein the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog.
12. The method of claim 11 , wherein the steps of activating the latent thiol groups and reacting the activated thiol groups occur essentially simultaneously.
13. The method of claim 12 , wherein the solid support is formed from a compound selected from the group consisting of glass, plastic and metal.
14. The method of claim 13 , wherein the solid support comprises two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids.
15. The method of claim 14 , wherein the solid support further comprises a polymer layer.
16. The method of claim 15 , wherein the solid support comprises a microarray.
17. The product formed by the method of claim 10 .
18. A method of immobilizing an affinity ligand on microarray comprising the steps of:
providing a solid support comprising immobilized latent thiol groups;
activating the latent thiol groups; and
reacting the activated thiol groups with an affinity ligand having at least one α,β unsaturated carbonyl functional group, thereby immobilizing an affinity ligand on a solid support.
19. The method of claim 18 , wherein the ligand is selected from the group consisting of a nucleic acid, a modified nucleic acid and a nucleic acid analog.
20. The method of claim 19 , wherein the steps of activating the latent thiol groups and reacting the activated thiol groups occur essentially simultaneously.
21. The method of claim 10 , further comprising the steps of:
contacting a glass solid support with a silane compound represented by the following structural formula:
wherein:
X is a halogen; and
RI, R, and R, are each, independently, a halogen, an alkyl group. an alkenyl group or a group having at least one α,β-unsaturated carbonyl, provided that at least one of RI, R, or R, is an alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface; and
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, disulfide bisacrylamide, and optionally an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
22. The method of claim 21 , wherein the latent thiol groups are activated by contacting the solid support with a disulfide reducing agent.
23. The method of claim 21 , wherein the polymerization solution further includes alkylene bisacrylamide.
24. The method of claim 21 , wherein the free radical initiator is added to the polymerization solution after the solution is in contact with the unsaturated aliphatic surface of the solid support.
25. The method of claim 21 , further comprising the step of derivatizing a solid support with a latent thiol group, thereby forming a solid support having immobilized latent thiol groups.
26. The method of claim 21 , wherein the solid support has an amine functional group and the solid support is derivatized by contacting the solid support with a compound represented by the following structural formula:
28. The method of claim 26 , wherein R, is selected from the group consisting of:
29. A method of preparing a solid support having immobilized thiol groups, comprising the steps of:
contacting a glass solid support with a silane compound represented by the following structural formula:
wherein:
X is a halogen; and
R1, R2, and R3, are each, independently, a halogen, an alkyl group, an alkenyl group or a group having at least one α,β-unsaturated carbonyl, provided that at least one of R1, R2, or R3 is an alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface;
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, disulfide bisacrylamide, and optionally an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein:
n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups; and contacting the latent thiol groups with a disulfide reducing agent, thereby forming a solid support having immobilized thiol groups.
30. The method of claim 29 , wherein a plurality of nucleic acids are immobilized on the solid support.
31. The method of claim 30 , wherein the solid support comprises two or more spatially distinct regions, each region comprising a plurality of immobilized nucleic acids.
32. The method of claim 29 , wherein the thiol groups comprise disulfide groups.
33. The method of claim 31 , wherein the latent thiol groups in selected regions of the support are activated, thereby providing a support comprising selected regions of reactive thiol groups.
34. A method of forming an array of nucleic acids immobilized on a solid support comprising:
forming an amine-derivatized region on the support;
treating the amine-derivatized region with a thiolating agent such that latent thiol groups immobilized on the support are formed;
activating the latent thiol groups;
contacting the activated thiol groups with a plurality of nucleic acids comprising acrylamide functional groups; and
forming a covalent bond between the two groups,
thereby forming an array of nucleic acids immobilized on the solid support.
35. The method of claim 34 , wherein each nucleic acid comprises a nucleotide sequence substantially identical to the nucleotide sequence of the other nucleic acids of the array.
36. The method of claim 34 , wherein nucleic acids with a plurality of nucleotide sequences are contained in the array.
37. The method of claim 34 comprising a plurality of amine-derivatized regions.
38. The method of claim 34 further comprising a step of blocking unbonded reactive thiol groups remaining following the binding of the nucleic acids to the thiol groups.
39. The microarray prepared by the method of claim 34 .
40. A kit for attaching nucleic acids to a solid support comprising a solid support component comprising a plurality of immobilized latent thiol groups and instructions for activating the thiol groups to form covalent bonds with nucleic acids comprising acrylamide functional groups.
41. The kit of claim 40 further comprising at least one component selected from the group consisting of an activator component, an acrylamide functional nucleic acids component, a blocking component, a wash buffer and a wash buffer.
42. A kit for attaching nucleic acids to a solid support comprising a solid support component comprising a plurality of immobilized thiol groups and nucleic acids comprising acrylamide functional groups.
43. The kit of claim 42 , wherein the nucleic acids are immobilized on a solid support by a covalent bond between the immobilized thiol groups and the nucleic acids.
44. The kit of claim 43 further comprising at least one component selected from the group consisting of an activator component, an acrylamide functional nucleic acids component, a blocking component and a wash buffer.
45. A method for detecting or separating target nucleic acids from other components contained in a sample comprising:
providing a solid support comprising a plurality of immobilized nucleic acids comprising nucleotide sequences complementary to a subsequence of the nucleotide sequence of the target nucleic acid, wherein the nucleic acids are immobilized by a covalent bond formed between a thiol group immobilized on the solid support and an acrylamide functional group contained on the nucleic acid;
contacting the immobilized nucleic acid with the sample; and
hybridizing target nucleic acids to immobilized nucleic acids with complementary subsequences,
thereby detecting or separating target nucleic acids from other components contained in the sample.
46. The method of claim 45 , wherein the target nucleic acids are amplified after detection or separation.
47. The method of claim 45 , wherein the method is used in an assay selected from the group of assays for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
48. A method for detecting or separating target nucleic acids from other components contained in a sample comprising:
providing a solid support comprising a plurality of immobilized thiol groups;
contacting the thiol groups with a plurality of nucleic acids comprising nucleotide sequences complementary to a subsequence of the nucleotide sequence of the target nucleic acid and acrylamide functional groups;
forming a covalent bond between the thiol and acrylamide functional groups, thereby immobilizing the nucleic acids on the solid support;
contacting the immobilized nucleic acids with the sample; and
hybridizing target nucleic acids to immobilized nucleic acids with complementary subsequences,
thereby detecting or separating target nucleic acids from other components contained in the sample.
49. The method of claim 48 , wherein the target nucleic acids are amplified after detection or separation.
50. The method of claim 49 , wherein the method is used in an assay selected from the group of assays for detecting a contaminant in a sample, for medical diagnosis of a medical condition, for genetic and physical mapping of genomes, for monitoring gene expression and for DNA sequencing.
51. The method of claim 10 , wherein the solid support is doped or undoped silica, alumina, quartz or glass, and wherein the method further comprises the steps of:
contacting the solid support with a compound comprising a silane group or a carboxylic acid and a substituted or unsubstituted alkenyl group or a group having at least one (α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface; and
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein:
n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
52. The method of claim 51 , wherein the compound is represented by the following structural formula:
wherein:
X is a halogen; and
RI, R2 and R3 are each, independently, a halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group or a group having at least one a,P-unsaturated carbonyl, provided that at least one of RI, R2 or R3 is a substituted or unsubstituted alkenyl group or a group having at least one a,p-unsaturated carbonyl.
53. The method of claim 51 , wherein the latent thiol groups are activated by contacting the solid support with a disulfide reducing agent.
54. The method of claim 51 , wherein the polymerization solution further includes alkylene bisacrylamide.
55. The method of claim 51 , wherein the free radical initiator is added to the polymerization solution after the solution is in contact with the unsaturated aliphatic surface of the solid support.
56. The method of claim 10 , wherein the solid support is selected from the group consisting of gold, silver, copper, cadmium, zinc, palladium, platinum, mercury, lead, iron, chromium, manganese, tungsten, and alloys thereof, and wherein the method further comprises the steps of:
contacting the solid support with a compound comprising a thiol group, sulfide or disulfide group and a substituted or unsubstituted alkenyl group or a group having at least one (x,p-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface; and
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing a conmonomer, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein:
n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
57. The method of claim 10 , wherein the solid support is selected from the group consisting of platinum or palladium, and wherein the method further comprises the steps of:
contacting the solid support with a compound comprising a nitrile or isonitrile group and a substituted or unsubstituted alkenyl group or a group having at least one a,p-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface; and
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein:
n and m in are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
58. The method of claim 10 , wherein the solid support is copper, and wherein the method further comprises the steps of:
contacting the solid support with a compound comprising a hydroxamic acid group and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface; and
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator and disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein n and mn are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
59. The method of claim 10 , wherein the solid support is a polymer comprising a reactive functional group, and wherein the method further comprises the steps of:
contacting the solid support with a compound comprising a functional group which can react to form a bond with the reactive functional group and a substituted or unsubstituted alkenyl group or a group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having immobilized unsaturated aliphatic groups; and
contacting the unsaturated aliphatic groups of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
wherein:
n and m are each, independently, a positive integer, thereby forming a solid support comprising immobilized latent thiol groups.
60. The method of claim 59 , wherein the polymeric solid support is polystyrene.
61. The method of claim 59 , wherein hod of claim 59 , wherein the reactive functional group of the polymeric solid support is an amine group or a hydroxyl group and the compound is represented by the following structural formula:
62. The compound of claim 61 , wherein Y is selected from the group consisting of:
wherein R6 and R7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
63. The method of claim 10 , further comprising the step of derivatizing a solid support with a latent thiol group, thereby forming a solid support having immobilized latent thiol groups.
64. The method of claim 63 , wherein the solid support is selected from the group consisting of doped or undoped silica, alumina, quartz or glass, and the solid support is derivatized by contacting it with a compound comprising a silane group or a carboxylic acid group and a latent thiol group.
65. The method of claim 63 , wherein the solid support is selected from the group consisting of platinum or palladium, and the solid support is derivatized by contacting it with a compound comprising a nitrile or isonitrile group and a latent thiol group.
66. The method of claim 63 , wherein the solid support is a polymer comprising reactive functional groups, and the solid support is derivatized by contacting it with a compound comprising a functional group which can react to form a bond with the reactive functional group and a latent thiol group.
67. The method of claim 63 , wherein the polymeric solid support is polystyrene.
68. The method of claim 66 , wherein the reactive functional group of the polymeric solid support is an amine or a hydroxyl group and the solid support is derivatized by contacting the solid support with a compound represented by the following structural formula:
69. The method of claim 68 , wherein Y is selected form the group consisting of:
wherein R6 and R7 are each, independently, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heteroaralkyl group.
70. The method of claim 68 , wherein is selected from the group consisting of:
71. A method of making a solid support having immobilized thiol groups, comprising the steps of:
contacting a glass solid support with a silane compound represented by the following structural formula:
wherein:
X is a halogen; and
R1, R2 and R3 are each, independently, a halogen, an alkyl group, an alkenyl group or a group having at least one α,β-unsaturated carbonyl, provided that at least one of RI, R, or R, is an alkenyl group or group having at least one α,β-unsaturated carbonyl, thereby forming a solid support having an unsaturated aliphatic surface;
contacting the unsaturated aliphatic surface of the solid support with a polymerization solution containing free radical initiator, a disulfide bisacrylamide and optionally containing an acrylamide, wherein the disulfide bisacrylamide is represented by the following structural formula:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/210,307 US20030143569A1 (en) | 1999-08-27 | 2002-08-01 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15126799P | 1999-08-27 | 1999-08-27 | |
| US17784400P | 2000-01-25 | 2000-01-25 | |
| US09/649,637 US6492118B1 (en) | 1999-08-27 | 2000-08-28 | Methods of immobilizing ligands on solid supports |
| US10/210,307 US20030143569A1 (en) | 1999-08-27 | 2002-08-01 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/649,637 Division US6492118B1 (en) | 1999-08-27 | 2000-08-28 | Methods of immobilizing ligands on solid supports |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030143569A1 true US20030143569A1 (en) | 2003-07-31 |
Family
ID=26848471
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/649,637 Expired - Lifetime US6492118B1 (en) | 1999-08-27 | 2000-08-28 | Methods of immobilizing ligands on solid supports |
| US10/210,400 Abandoned US20030143570A1 (en) | 1999-08-27 | 2002-08-01 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor |
| US10/210,307 Abandoned US20030143569A1 (en) | 1999-08-27 | 2002-08-01 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/649,637 Expired - Lifetime US6492118B1 (en) | 1999-08-27 | 2000-08-28 | Methods of immobilizing ligands on solid supports |
| US10/210,400 Abandoned US20030143570A1 (en) | 1999-08-27 | 2002-08-01 | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6492118B1 (en) |
| EP (1) | EP1208238B1 (en) |
| JP (1) | JP2003508763A (en) |
| AT (1) | ATE414171T1 (en) |
| CA (1) | CA2382121A1 (en) |
| DE (1) | DE60040794D1 (en) |
| WO (1) | WO2001016372A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241713A1 (en) * | 2001-07-25 | 2004-12-02 | Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Rossiiskoi Akademii Nauk | Composition for immobilization of biological macromolecules in hydrogels, a method for preparing a composition, a biochip, and a method for performing the PCR over biochip |
| US20070238163A1 (en) * | 2006-04-05 | 2007-10-11 | Golova Julia B | Covalent attachment of biomolecules to solid supports by a polymerization method |
| US20070276829A1 (en) * | 2004-03-31 | 2007-11-29 | Niniane Wang | Systems and methods for ranking implicit search results |
| WO2018098473A1 (en) * | 2016-11-28 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes |
| US20230213438A1 (en) * | 2019-04-29 | 2023-07-06 | Nautilus Biotechnology, Inc. | Methods and systems for integrated on-chip single-molecule detection |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| US20020012971A1 (en) * | 2000-03-20 | 2002-01-31 | Mehta Tammy Burd | PCR compatible nucleic acid sieving medium |
| WO2002027026A2 (en) * | 2000-09-28 | 2002-04-04 | Matrix Technologies Corporation | Improved support for solid phase hybridization assays |
| DE60039792D1 (en) * | 2000-10-23 | 2008-09-18 | Ingeny Holding Bv | METHOD AND DEVICE FOR DETECTING MUTATIONS IN NUCLEIC ACID SAMPLES |
| EP1245272A1 (en) * | 2001-03-30 | 2002-10-02 | Ucb S.A. | Substrates, preparation and use |
| US7297311B2 (en) * | 2001-06-29 | 2007-11-20 | Sysmex Corporation | Automatic smear preparing apparatus and automatic sample analysis system having the same |
| US10272409B2 (en) | 2001-07-11 | 2019-04-30 | Michael E. Hogan | Methods and devices based upon a novel form of nucleic acid duplex on a surface |
| AU2002318306B2 (en) * | 2001-07-11 | 2008-06-19 | Baylor College Of Medicine | Methods and devices based upon a novel form of nucleic acid duplex on a surface |
| US6995248B2 (en) | 2001-07-16 | 2006-02-07 | Dr. Chip Biotechnology, Inc. | Immobilization of nucleic acids |
| DE60118901T2 (en) * | 2001-07-16 | 2006-11-23 | Dr. Chip Biotechnology Inc. | Immobilization of Oligonucleotides by Covalent Bonding |
| US7341552B2 (en) * | 2002-03-15 | 2008-03-11 | The University Of Texas System Board Of Regents | Gene sets for glioma classification |
| US7371852B2 (en) * | 2003-01-22 | 2008-05-13 | Serenex, Inc. | Alkyl-linked nucleotide compositions |
| SE0300624D0 (en) | 2003-03-05 | 2003-03-05 | Amersham Biosciences Ab | A method of preparing affinity ligands |
| US20050112786A1 (en) * | 2003-11-25 | 2005-05-26 | Qing Wang | Method of immobilizing a substance of interest to a solid phase |
| TW200521433A (en) * | 2003-12-22 | 2005-07-01 | We Gene Technologies Inc | Cell detection chip and fabricating method thereof and method of detecting cell |
| GB0410448D0 (en) * | 2004-05-11 | 2004-06-16 | Hammersmith Imanet Ltd | Purification methods |
| US7579224B2 (en) * | 2005-01-21 | 2009-08-25 | Semiconductor Energy Laboratory Co., Ltd. | Method for manufacturing a thin film semiconductor device |
| US8268604B2 (en) * | 2007-12-20 | 2012-09-18 | Abbott Point Of Care Inc. | Compositions for forming immobilized biological layers for sensing |
| US8241697B2 (en) | 2007-12-20 | 2012-08-14 | Abbott Point Of Care Inc. | Formation of immobilized biological layers for sensing |
| JP2009156767A (en) * | 2007-12-27 | 2009-07-16 | National Institute Of Advanced Industrial & Technology | Protein array substrate |
| RU2451010C1 (en) * | 2011-01-11 | 2012-05-20 | Закрытое Акционерное Общество "Ива Фарм" | Palladium-copper catalysts for homogeneous selective oxidation of thiol groups, combination and composition based on said catalysts and therapeutic treatment method |
| US20140378349A1 (en) * | 2012-08-14 | 2014-12-25 | 10X Technologies, Inc. | Compositions and methods for sample processing |
| US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| EP3901273A1 (en) | 2012-08-14 | 2021-10-27 | 10X Genomics, Inc. | Microcapsule compositions and methods |
| US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US20150005199A1 (en) * | 2012-08-14 | 2015-01-01 | 10X Technologies, Inc. | Compositions and methods for sample processing |
| US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| WO2014093676A1 (en) | 2012-12-14 | 2014-06-19 | 10X Technologies, Inc. | Methods and systems for processing polynucleotides |
| US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| CN105102697A (en) | 2013-02-08 | 2015-11-25 | 10X基因组学有限公司 | Polynucleotide barcode generation |
| WO2014138028A1 (en) * | 2013-03-04 | 2014-09-12 | The Scripps Research Institute | Liquid array platform for multiplexed analysis of molecule-protein interactions |
| US10395758B2 (en) | 2013-08-30 | 2019-08-27 | 10X Genomics, Inc. | Sequencing methods |
| ES2537097B1 (en) * | 2013-10-30 | 2016-04-05 | Universitat Politècnica De València | METHOD OF SURFACE CHEMICAL ACTIVATION OF A SOLID SILICON BASED SUPPORT THROUGH DIRECT COVALENT ANCHORAGE OF AT LEAST ONE NUCLEIC ACID BIOMOLECLE. |
| US9824068B2 (en) | 2013-12-16 | 2017-11-21 | 10X Genomics, Inc. | Methods and apparatus for sorting data |
| BR112016023625A2 (en) | 2014-04-10 | 2018-06-26 | 10X Genomics, Inc. | fluidic devices, systems and methods for encapsulating and partitioning reagents, and applications thereof |
| JP2017522866A (en) | 2014-06-26 | 2017-08-17 | 10エックス ジェノミクス, インコーポレイテッド | Nucleic acid sequence analysis |
| US12312640B2 (en) | 2014-06-26 | 2025-05-27 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| EP3889325A1 (en) | 2014-06-26 | 2021-10-06 | 10X Genomics, Inc. | Methods of analyzing nucleic acids from individual cells or cell populations |
| CN114807307A (en) | 2014-10-29 | 2022-07-29 | 10X 基因组学有限公司 | Methods and compositions for sequencing target nucleic acids |
| US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
| BR112017014902A2 (en) | 2015-01-12 | 2018-03-13 | 10X Genomics Inc | processes and systems for the preparation of nucleic acid sequencing libraries and libraries prepared using them |
| EP3262407B1 (en) | 2015-02-24 | 2023-08-30 | 10X Genomics, Inc. | Partition processing methods and systems |
| AU2016222719B2 (en) | 2015-02-24 | 2022-03-31 | 10X Genomics, Inc. | Methods for targeted nucleic acid sequence coverage |
| US11371094B2 (en) | 2015-11-19 | 2022-06-28 | 10X Genomics, Inc. | Systems and methods for nucleic acid processing using degenerate nucleotides |
| ES2926495T3 (en) | 2015-12-04 | 2022-10-26 | 10X Genomics Inc | Methods and compositions for nucleic acid analysis |
| JP6735348B2 (en) | 2016-02-11 | 2020-08-05 | 10エックス ジェノミクス, インコーポレイテッド | Systems, methods and media for de novo assembly of whole genome sequence data |
| WO2017197343A2 (en) | 2016-05-12 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic on-chip filters |
| WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
| US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US12264411B2 (en) | 2017-01-30 | 2025-04-01 | 10X Genomics, Inc. | Methods and systems for analysis |
| EP3545089B1 (en) | 2017-01-30 | 2022-03-09 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
| US10995333B2 (en) | 2017-02-06 | 2021-05-04 | 10X Genomics, Inc. | Systems and methods for nucleic acid preparation |
| EP4230746A3 (en) | 2017-05-26 | 2023-11-01 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
| US10400235B2 (en) | 2017-05-26 | 2019-09-03 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
| US10590244B2 (en) | 2017-10-04 | 2020-03-17 | 10X Genomics, Inc. | Compositions, methods, and systems for bead formation using improved polymers |
| US10837047B2 (en) | 2017-10-04 | 2020-11-17 | 10X Genomics, Inc. | Compositions, methods, and systems for bead formation using improved polymers |
| WO2019084043A1 (en) | 2017-10-26 | 2019-05-02 | 10X Genomics, Inc. | Methods and systems for nuclecic acid preparation and chromatin analysis |
| WO2019084165A1 (en) | 2017-10-27 | 2019-05-02 | 10X Genomics, Inc. | Methods and systems for sample preparation and analysis |
| EP3625361A1 (en) | 2017-11-15 | 2020-03-25 | 10X Genomics, Inc. | Functionalized gel beads |
| US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
| WO2019108851A1 (en) | 2017-11-30 | 2019-06-06 | 10X Genomics, Inc. | Systems and methods for nucleic acid preparation and analysis |
| EP3724658A1 (en) | 2017-12-12 | 2020-10-21 | 10X Genomics, Inc. | Systems and methods for single cell processing |
| CN118547046A (en) | 2017-12-22 | 2024-08-27 | 10X基因组学有限公司 | Systems and methods for processing nucleic acid molecules from one or more cells |
| CN112005115A (en) | 2018-02-12 | 2020-11-27 | 10X基因组学有限公司 | Methods to characterize multiple analytes from single cells or cell populations |
| US11639928B2 (en) | 2018-02-22 | 2023-05-02 | 10X Genomics, Inc. | Methods and systems for characterizing analytes from individual cells or cell populations |
| WO2019169028A1 (en) | 2018-02-28 | 2019-09-06 | 10X Genomics, Inc. | Transcriptome sequencing through random ligation |
| SG11202009889VA (en) | 2018-04-06 | 2020-11-27 | 10X Genomics Inc | Systems and methods for quality control in single cell processing |
| WO2019217758A1 (en) | 2018-05-10 | 2019-11-14 | 10X Genomics, Inc. | Methods and systems for molecular library generation |
| US11932899B2 (en) | 2018-06-07 | 2024-03-19 | 10X Genomics, Inc. | Methods and systems for characterizing nucleic acid molecules |
| US11703427B2 (en) | 2018-06-25 | 2023-07-18 | 10X Genomics, Inc. | Methods and systems for cell and bead processing |
| US12188014B1 (en) | 2018-07-25 | 2025-01-07 | 10X Genomics, Inc. | Compositions and methods for nucleic acid processing using blocking agents |
| US20200032335A1 (en) | 2018-07-27 | 2020-01-30 | 10X Genomics, Inc. | Systems and methods for metabolome analysis |
| US12163179B2 (en) | 2018-08-03 | 2024-12-10 | 10X Gemomics, Inc. | Methods and systems to minimize barcode exchange |
| US12065688B2 (en) | 2018-08-20 | 2024-08-20 | 10X Genomics, Inc. | Compositions and methods for cellular processing |
| WO2020041148A1 (en) | 2018-08-20 | 2020-02-27 | 10X Genomics, Inc. | Methods and systems for detection of protein-dna interactions using proximity ligation |
| US11459607B1 (en) | 2018-12-10 | 2022-10-04 | 10X Genomics, Inc. | Systems and methods for processing-nucleic acid molecules from a single cell using sequential co-partitioning and composite barcodes |
| US12169198B2 (en) | 2019-01-08 | 2024-12-17 | 10X Genomics, Inc. | Systems and methods for sample analysis |
| US11845983B1 (en) | 2019-01-09 | 2023-12-19 | 10X Genomics, Inc. | Methods and systems for multiplexing of droplet based assays |
| US11851683B1 (en) | 2019-02-12 | 2023-12-26 | 10X Genomics, Inc. | Methods and systems for selective analysis of cellular samples |
| WO2020168013A1 (en) | 2019-02-12 | 2020-08-20 | 10X Genomics, Inc. | Methods for processing nucleic acid molecules |
| US11467153B2 (en) | 2019-02-12 | 2022-10-11 | 10X Genomics, Inc. | Methods for processing nucleic acid molecules |
| WO2020167862A1 (en) | 2019-02-12 | 2020-08-20 | 10X Genomics, Inc. | Systems and methods for transfer of reagents between droplets |
| WO2020167866A1 (en) | 2019-02-12 | 2020-08-20 | 10X Genomics, Inc. | Systems and methods for transposon loading |
| US12275993B2 (en) | 2019-02-12 | 2025-04-15 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| US12305239B2 (en) | 2019-02-12 | 2025-05-20 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| US11655499B1 (en) | 2019-02-25 | 2023-05-23 | 10X Genomics, Inc. | Detection of sequence elements in nucleic acid molecules |
| EP3938537A1 (en) | 2019-03-11 | 2022-01-19 | 10X Genomics, Inc. | Systems and methods for processing optically tagged beads |
| US12235262B1 (en) | 2019-09-09 | 2025-02-25 | 10X Genomics, Inc. | Methods and systems for single cell protein analysis |
| WO2021153717A1 (en) * | 2020-01-31 | 2021-08-05 | 池田 壽文 | Affinity chromatography based on artificial nucleic acid |
| US12449419B1 (en) | 2020-02-12 | 2025-10-21 | 10X Genomics, Inc. | Methods for detecting binding of peptide-MHC monomers to T cells |
| US11851700B1 (en) | 2020-05-13 | 2023-12-26 | 10X Genomics, Inc. | Methods, kits, and compositions for processing extracellular molecules |
| US12084715B1 (en) | 2020-11-05 | 2024-09-10 | 10X Genomics, Inc. | Methods and systems for reducing artifactual antisense products |
| US12480158B1 (en) | 2020-11-05 | 2025-11-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US12398262B1 (en) | 2021-01-22 | 2025-08-26 | 10X Genomics, Inc. | Triblock copolymer-based cell stabilization and fixation system and methods of use thereof |
| EP4298244A1 (en) | 2021-02-23 | 2024-01-03 | 10X Genomics, Inc. | Probe-based analysis of nucleic acids and proteins |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4667025A (en) * | 1982-08-09 | 1987-05-19 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4898824A (en) * | 1986-12-09 | 1990-02-06 | Miles Inc. | Crosslinked polyacrylamide-sulfhydryl polymer for immobilization of biologically active substances |
| US5034428A (en) * | 1986-06-19 | 1991-07-23 | Board Of Regents Of The University Of Washington | Immobilized biomolecules and method of making same |
| US5176966A (en) * | 1990-11-19 | 1993-01-05 | Ballard Power Systems Inc. | Fuel cell membrane electrode and seal assembly |
| US5324650A (en) * | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
| US5478893A (en) * | 1989-01-05 | 1995-12-26 | Siska Diagnostics Inc. | End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids |
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| US5599695A (en) * | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5728296A (en) * | 1996-03-20 | 1998-03-17 | Bio-Rad Laboratories, Inc. | Selective recognition of solutes in chromatographic media by artificially created affinity |
| US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5837860A (en) * | 1997-03-05 | 1998-11-17 | Molecular Tool, Inc. | Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds |
| US5858653A (en) * | 1997-09-30 | 1999-01-12 | Surmodics, Inc. | Reagent and method for attaching target molecules to a surface |
| US5932711A (en) * | 1997-03-05 | 1999-08-03 | Mosaic Technologies, Inc. | Nucleic acid-containing polymerizable complex |
| US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| US6040138A (en) * | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US6083763A (en) * | 1996-12-31 | 2000-07-04 | Genometrix Inc. | Multiplexed molecular analysis apparatus and method |
| US6093370A (en) * | 1998-06-11 | 2000-07-25 | Hitachi, Ltd. | Polynucleotide separation method and apparatus therefor |
| US6266131B1 (en) * | 1994-12-14 | 2001-07-24 | Nikon Corporation | Exposure apparatus |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268131B1 (en) * | 1997-12-15 | 2001-07-31 | Sequenom, Inc. | Mass spectrometric methods for sequencing nucleic acids |
-
2000
- 2000-08-28 EP EP00957879A patent/EP1208238B1/en not_active Expired - Lifetime
- 2000-08-28 US US09/649,637 patent/US6492118B1/en not_active Expired - Lifetime
- 2000-08-28 CA CA002382121A patent/CA2382121A1/en not_active Abandoned
- 2000-08-28 DE DE60040794T patent/DE60040794D1/en not_active Expired - Lifetime
- 2000-08-28 WO PCT/US2000/023627 patent/WO2001016372A1/en not_active Ceased
- 2000-08-28 JP JP2001520917A patent/JP2003508763A/en active Pending
- 2000-08-28 AT AT00957879T patent/ATE414171T1/en not_active IP Right Cessation
-
2002
- 2002-08-01 US US10/210,400 patent/US20030143570A1/en not_active Abandoned
- 2002-08-01 US US10/210,307 patent/US20030143569A1/en not_active Abandoned
Patent Citations (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4667025A (en) * | 1982-08-09 | 1987-05-19 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4789737A (en) * | 1982-08-09 | 1988-12-06 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives and production thereof |
| US4820812A (en) * | 1982-08-09 | 1989-04-11 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives and production thereof |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683202B1 (en) * | 1985-03-28 | 1990-11-27 | Cetus Corp | |
| US5034428A (en) * | 1986-06-19 | 1991-07-23 | Board Of Regents Of The University Of Washington | Immobilized biomolecules and method of making same |
| US4898824A (en) * | 1986-12-09 | 1990-02-06 | Miles Inc. | Crosslinked polyacrylamide-sulfhydryl polymer for immobilization of biologically active substances |
| US5478893A (en) * | 1989-01-05 | 1995-12-26 | Siska Diagnostics Inc. | End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids |
| US5324650A (en) * | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
| US5176966A (en) * | 1990-11-19 | 1993-01-05 | Ballard Power Systems Inc. | Fuel cell membrane electrode and seal assembly |
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6266131B1 (en) * | 1994-12-14 | 2001-07-24 | Nikon Corporation | Exposure apparatus |
| US5599695A (en) * | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US6040138A (en) * | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US6013440A (en) * | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
| US5728296A (en) * | 1996-03-20 | 1998-03-17 | Bio-Rad Laboratories, Inc. | Selective recognition of solutes in chromatographic media by artificially created affinity |
| US6083763A (en) * | 1996-12-31 | 2000-07-04 | Genometrix Inc. | Multiplexed molecular analysis apparatus and method |
| US5837860A (en) * | 1997-03-05 | 1998-11-17 | Molecular Tool, Inc. | Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds |
| US5932711A (en) * | 1997-03-05 | 1999-08-03 | Mosaic Technologies, Inc. | Nucleic acid-containing polymerizable complex |
| US6030782A (en) * | 1997-03-05 | 2000-02-29 | Orchid Biocomputer, Inc. | Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds |
| US5858653A (en) * | 1997-09-30 | 1999-01-12 | Surmodics, Inc. | Reagent and method for attaching target molecules to a surface |
| US6093370A (en) * | 1998-06-11 | 2000-07-25 | Hitachi, Ltd. | Polynucleotide separation method and apparatus therefor |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241713A1 (en) * | 2001-07-25 | 2004-12-02 | Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Rossiiskoi Akademii Nauk | Composition for immobilization of biological macromolecules in hydrogels, a method for preparing a composition, a biochip, and a method for performing the PCR over biochip |
| US20070276829A1 (en) * | 2004-03-31 | 2007-11-29 | Niniane Wang | Systems and methods for ranking implicit search results |
| US20070238163A1 (en) * | 2006-04-05 | 2007-10-11 | Golova Julia B | Covalent attachment of biomolecules to solid supports by a polymerization method |
| WO2018098473A1 (en) * | 2016-11-28 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes |
| US10969394B2 (en) | 2016-11-28 | 2021-04-06 | Dana-Farber Cancer Institute, Inc. | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes |
| US11789025B2 (en) | 2016-11-28 | 2023-10-17 | Dana-Farber Cancer Institute, Inc. | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes |
| US20230213438A1 (en) * | 2019-04-29 | 2023-07-06 | Nautilus Biotechnology, Inc. | Methods and systems for integrated on-chip single-molecule detection |
| US12306093B2 (en) | 2019-04-29 | 2025-05-20 | Nautilus Subsidiary, Inc. | Methods and systems for integrated on-chip single-molecule detection |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030143570A1 (en) | 2003-07-31 |
| JP2003508763A (en) | 2003-03-04 |
| DE60040794D1 (en) | 2008-12-24 |
| CA2382121A1 (en) | 2001-03-08 |
| EP1208238A1 (en) | 2002-05-29 |
| EP1208238B1 (en) | 2008-11-12 |
| WO2001016372A9 (en) | 2002-09-12 |
| WO2001016372A1 (en) | 2001-03-08 |
| US6492118B1 (en) | 2002-12-10 |
| ATE414171T1 (en) | 2008-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6492118B1 (en) | Methods of immobilizing ligands on solid supports | |
| US6413722B1 (en) | Polymer coated surfaces for microarray applications | |
| JP5588430B2 (en) | Surface and method for label independent detection | |
| US9834617B2 (en) | Method for immobilizing biologic molecules on solid surfaces | |
| US6692912B1 (en) | Nucleic acid-containing polymerizable complex | |
| RU2206575C2 (en) | Composition for immobilization of biological macromolecule in hydrogel, method for preparing composition, biochip, method for carrying out polymerase chain reaction (pcr) on biochip | |
| JP2001513109A (en) | Nucleic acid-containing polymerizable complex | |
| MXPA01007638A (en) | Replicable probe array. | |
| JP2009522547A (en) | Support for analyte assay and method for producing and using the same | |
| KR20140137366A (en) | Polymer scaffolds for assay applications | |
| US20070048747A1 (en) | Methods for assaying analytes | |
| US7785769B2 (en) | Immobilization of oligonucleotides and proteins in sugar-containing hydrogels | |
| EP1644527B1 (en) | Cucurbituril derivative-bonded solid substrate and biochip using the same | |
| AU780882B2 (en) | Methods of immobilizing ligands on solid supports and apparatus and methods of use therefor | |
| WO2004079367A1 (en) | Bioarray | |
| US20060111517A1 (en) | Recognition layers made of hydrogel based on polyacrylamide for use in biosensor technology | |
| Peris et al. | Photopolymerization as a promising method to sense biorecognition events | |
| US20030003480A1 (en) | Reactive solid support and DNA fragment detection tool | |
| RU2004134192A (en) | NANODIAGNOSTIC TEST SYSTEM FOR HEPATITIS VIRUS IDENTIFICATION | |
| CN101253275A (en) | Method for fixing a supercoiled DNA and the use for analysing the dna repair | |
| JP4397006B2 (en) | Method for producing bio-related substance-immobilized gel | |
| WO2021085526A1 (en) | Biochip and detection method | |
| Chen et al. | Immobilization of aptamers onto unmodified glass surfaces for affordable biosensors | |
| JP2003194815A (en) | Reactive solid phase carrier and dna fragment detecting tool | |
| Feng et al. | Peptides at Material Surfaces |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |